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Publication No.______
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Supervisory Professor: Frank C. Marini III, Ph.D.
The tumor microenvironment is comprised of a vast array of heterogeneous
cells including both normal and neoplastic cells.

The tumor stroma recruitment

process has been exploited for an effective gene delivery technique using bone
marrow derived MSC. Targeted migration of the MSC toward the tumor
microenvironment, while successful, is not yet fully understood. This study was
designed to assess the role of CD44 in the migration of MSC toward the tumor
microenvironment and to determine the implications of CD44-deficient MSC within
the tumor stroma.

Inhibition of MSC migration was evaluated through a variety of

methods in vitro and in vivo including CD44 receptor knockdown, CD44 antagonists,
CD44

neutralizing

metalloproteinases.

antibodies

and

small

molecule

inhibitor

of

matrix

Blocking CD44 signaling through MMP inhibition was

characterized by lack of intracellular domain cleavage and lead to the decrease in
Twist gene expression. A functional relationship between CD44 and Twist
expression was confirmed by chromatin immunoprecipitation.
Next, a series of murine tumor models were used to examine the role of CD44
deficient stroma within the tumor microenvironment.

Labeled transgenic CD44

knockout (KO) MSC or wild type (WT) C57/b6 MSC were used to analyze the
stromal incorporation within murine breast carcinomas (EO771 and 4T1).
Subsequent tumors were analyzed for vessel formation (CD31), and the presence of
tumor associated fibroblast (TAF) markers, α-smooth muscle actin (α-SMA),
fibroblast activation protein (FAP), and fibroblast specific protein (FSP). The tumors
with CD44KO MSC cells had less vessel formation than the tumors with WT MSC.
The lack of fibroblastic TAF population as defined by FAP/FSP expression by the
vi

CD44KO MSC admixed tumors suggest that the bone marrow derived population of
MSC were unable to contribute to the fibroblastic stromal population. Subsequently,
a bone marrow transplantation experiment confirmed the endogenous migratory
deficiencies of the CD44KO bone marrow derived stromal cells toward the tumor
microenvironment in vivo. WT mice with CD44KO bone marrow had less CD44KOderived tumor stroma compared to mice with WT bone marrow. These results
indicate that CD44 is crucial to stromal cell migration and incorporation to the tumor
microenvironment as TAF.
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1.

Introduction

1.1

Cancer Biology

In the United States, cancer accounts for almost 1 of every 4 deaths. (1) In women,
over a quarter of newly diagnosed cancer patients will have breast cancer.
Furthermore, there is a strong correlation between primary breast cancer survivors
and the risk of subsequent cancers including ovarian cancer. While ovarian cancer
affects a smaller proportion of women, it has a high mortality rate compared to other
cancers inflicting women’s reproductive organs. In these studies, we utilize both
breast and ovarian cancer models to elucidate the interaction between the cancer
and surrounding normal tissues in which the cancer subsists. By bettering our
understanding of the tumor’s microenvironment, we will enhance our ability to
provide anticancer treatments.
Cancer is defined by a series of “hallmarks;” as described by Hanahan and
Weinberg in 2000 these include the acquisition of self-sufficient growth, insensitivity
to anti-growth signals, ability to invade and metastasize, replicate indefinitely,
maintain angiogenesis and evade apoptosis. (2) These traits are vital to the growth
and progression of cancer cells, and have been used as the basis for several anticancer therapies targeting proliferation, anti-apoptosis and angiogenesis. However,
because the cancer cell does not sustain itself in isolation from normal cells in the
body, interactions between normal and neoplastic cells within the tumor’s
microenvironment is likely involved in the progression and growth of the tumor and
furthermore involved in the evasion of anti-tumor therapies.
1.2

Tumor microenvironment

The theory of microenvironment interactions with tumor cells extends from the late
1800s when Stephen Paget proposed the ‘seed and soil’ hypothesis suggesting that
the cancer cells (seeds) need the appropriate environment (soil) for survival.
Investigators now acknowledge that the idea of metastatic tumor cells is not a
random, passive process, but that tumor cells engage with a microenvironment that
1

fits the needed homeostatic balance. When the criteria are filled, the cancer cell
finds a home in a pro-growth, pro-angiogenic, pro-survival environment that is
perhaps at first permissive to tumor growth but over time may become supportive to
tumor growth.

Allowing the outgrowth of the tumor is a feature of the cancer

microenvironment when not only the cancer cells themselves express the 7
recognized “hallmarks of cancer,” but the “tumor activated” microenvironment
becomes tumor permissive.
The tumor microenvironment is composed of several cell types including fibroblast,
endothelial, myofibroblast and immune cells.

The tumor stroma provides

architectural and structural support as well as paracrine and juxtacrine growth
factors that support proliferation, angiogenesis and invasion and enhance
neovascularization (3, 4).

Tumor stromal fibroblast studies suggest these non-

neoplastic cells may not be normal, but may be “activated” by the tumor within
which they reside (5, 6). Identifying the tumor associated stromal populations—their
origin and their mechanism of interaction with and within the tumor may provide an
attractive anti-cancer therapy targeted against tumor specific stroma.
1.3

Origin of tumor stroma components

Tumor stroma can be recruited from the local, surrounding tissue or from distant
tissues through the circulation. The “local” tissue is a naturally convenient location
of stromal recruitment for a developing tumor. While anatomical location is variable
between tumor types, many tissues are rich in fibroblasts, pericytes and vascular
cells that may contribute to the microenvironment of a growing tumor. In an elegant
transplant model by Udagawa et al., tumors were engrafted into mice receiving a
GFP+ bone marrow transplant or adjacent to a GFP+ skin transplant. The tumors
adjacent to the GFP+ skin transplant had organized GFP+ vasculature as opposed
to hematopoietic derived GFP+ cells that were spatially unorganized and
unstructured (7).

2

Udagawa et al. did describe distant (bone marrow derived) recruitment of stromal
components into the tumor microenvironment, however incorporation was sparse.
As a tumor grows, the angiogenic demand increases leading to increased
vascularization that supplies blood, nutrients, oxygen and hematopoietic cells to the
tumor. The hematopoietic stem cell population resides in the bone marrow and
repopulates the blood lineages—several of which have been found in the tumor
stroma including macrophages and lymphocytes. The other main bone marrow
resident stem cell population includes the mesenchymal stem cell that repopulates
the connective tissue populations. IV injected bone marrow derived populations are
able to circulate and migrate to the tumor microenvironment (8, 9). Several studies
have

examined

the

incorporation

of

the

bone

marrow

to

the

tumor

microenvironments through transgenic models, or labeled bone marrow transplant
studies. Bone marrow derived cells have been found in gliomas (10), sarcomas
(11) and we have identified bone marrow derived populations in syngeneic breast
cancer models (unpublished data). Contradictory studies show the bone marrow
derived populations are incapable of participating in tumor endothelium (12). Further
evidence suggests that the bone marrow derived cells are indeed capable of not
only supporting tumor growth, but if mutated, are capable of forming tumors (13,
14).
Recruited from local neighboring tissue or distant tissue through the vascular or
lymphatic circulation, these stromal components are heterogeneous and will be
further divided into categories found within the tumor microenvironment including
those modulating the immune, vascular and structural characteristics of the tumor
and its microenvironment.
1.3.1 Immunomodulatory components
The chemotactic profile of the tumor is crucial to the induction of immune cell
migration into the tumor microenvironment. Several chemokines are suggested to
be involved in both the leukocyte infiltration and in immune surveillance—evading
detection by immune cells (15). The tumor stroma is an active participant in the
3

immune evasion technique employed by the tumor—fibroblast precursors such as
MSC have been shown to modulate dendritic cells, natural killer cells and T cells to
a more “tolerant” phenotype, thereby protecting the tumor (16).

Observing

leukocytes in tumor stroma in 1863, Rudolf Virchow suggested a link between
inflammation and cancer; his successors have since implicated leukocytes to play a
role in the promotion of tumor growth, angiogenesis and metastases (17, 18).
Immune cells including T lymphocytes and T helper cells have been isolated from
the breast cancer patient tumor microenvironment (19).
One such immune cell found in the tumor microenvironment is the macrophage.
The macrophage within the tumor microenvironment is shown to be a pro
tumorigenic component inducing angiogenesis and proliferation through paracrine
factor production. Furthermore, the macrophages immune-surveillance functions
are compromised by the tumor microenvironment, thus creating a tumor associated
macrophage (TAM) that supports tumor growth (20, 21). Reducing the inflammation
in the tumor microenvironment leads to decreased TAM infiltration that leads to
decreased tumor progression (21).
1.3.2 Structurally supportive components
The fibroblast expresses extracellular matrix (ECM) including collagen and laminin
and provides a structural bed on which tissues and organs are situated. The
function of the normal fibroblast is to repair wounded/inflamed tissues (22).
However, fibroblasts, along with other components of the tumor microenvironment,
have been implicated in the progression of tumorigenesis (23-26). The “activated”
fibroblast has been described by a number of surface markers (25) that include:
1- fibroblast and myofibroblast markers including fibroblast activation protein
(FAP), fibroblast specific protein (FSP) and alpha smooth muscle actin (α-SMA)
2- proteins associated with aggressive and invasive tumor phenotypes including
secreted matrix remodeling proteinases such as the matrix matalloroteinase
family

4

3- pro-growth paracrine factors including those that promote both proliferation and
vascularization including VEGF, PDGF and EGF
These markers have been associated with pathogenic fibroblasts as opposed to the
naïve fibroblast counterpart (6, 27); however, it appears that there may be several
non-overlapping markers associated with the “activated” fibroblast populations (28).
Activated fibroblasts can be defined as a heterogeneous population on many levels,
intra-tumorally within a single tumor and inter-tumorally between several tumor
subgroups. It is suspected that the tumor enlists participation of neighboring stromal
components and thus this population is defined by but not limited to the markers
described in the following sections.
The expression of the cell surface bound protease, FAP, is up regulated in activated
fibroblasts involved in tissue remodeling of pathogenic conditions including wound
healing of chronic inflammation and tumor development (29-31). The expression of
FAP has been identified on tumor stroma in several carcinomas including thyroid
(32) and colon (33) and has been used as an anti-tumor-stroma target in a breast
tumor microenvironment model (34).
Similar to FAP expression patterns on activated fibroblasts, FSP, also called
S100A4, is associated with aggressive and metastatic tumor phenotypes (35, 36).
FSP is a member of the S100 super family which is involved in calcium signal
transduction and cytoskeletal membrane interactions; it also functions in a paracrine
factor by promoting angiogenesis in its secreted form (37).
Yet another marker of activated fibroblasts is the intracellular contractile protein, αSMA.

While this protein is expressed at basal levels on fibroblasts, and on

myofibroblasts, the expression is up regulated under pathological states including
active wound healing. Under normal wound healing environments, following wound
contraction, as seen by an increase in α-SMA expression, the myofibroblasts
undergo apoptosis.

However, under TGF-β stimulation, the myofibroblast is

resistant to apoptosis (38) thereby causing constitutive inflammatory paracrine
5

factor secretion and persistent fibrosis. Furthermore, as TGF-β is a growth factor
secreted within the tumor microenvironment, it is reasonable to expect a correlation
between TGF-β, myofibroblast α-SMA expression and increased malignant
transformation (39).
1.3.3 Vascular supportive components
Neovascularization is a significant component in the growth and proliferation of a
tumor. Beyond a diameter of 1mm, a tumor must create its own blood supply for
nutrient exchange through angiogenesis (40). Both the tumor cells and the stromal
cells are capable of secreting pro-angiogenic factors like VEGF, which is a current
clinical target for many cancers (41, 42). Tumors rapidly vascularize in order to
maintain their nutrient and oxygen supply through angiogenic sprouting. Bone
marrow derived endothelial progenitor cells (EPC) have been shown to contribute to
the angiogenic switch in tumor growth and metastases (43, 44). The numbers of
EPC within a tumor as well as the number of circulating endothelial cells have been
shown to correlate with tumor stage (45).
Tumor induced neovascularization is a deregulated process in which the vessel
formation consists of endothelial cells, tumor cells and aberrant pericytes, such as
activated fibroblasts. The lack of proper vessel structure results in leaky and
inefficient vessels (46). Furthermore, permeable vessels can cause tumor interstitial
hypertension that can inhibit the delivery of anti-tumor agents such as
chemotherapy.

Interestingly,

inhibition

of

PDGFRβ

within

the

tumor

microenvironment has been shown to relieve this interstitial pressure and thus allow
the delivery of the chemotherapy (47). In a more recent study, combination therapy
with PDGF and VEGF antibody treatment has been shown to have additive effects
on tumor growth inhibition; furthermore, when used alone, anti-VEGF therapy is
believed to up regulate the PDGF secretion by the supportive stromal populations to
maintain angiogenic support (48).
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A myofibroblast, briefly described above as a tumor supportive fibroblast cell, has
often been confused with a vascular supportive cell known as the pericyte.
Furthermore, it also has very similar properties and is very likely one in the same as
the mesenchymal stem cell (49). The pericyte is a cell that helps to support the
vasculature by forming close contacts and with and surrounding the endothelial
cells comprising blood vessels. Pericytes can be defined by many of the same
markers as the myofibroblast including α-SMA. Interestingly, the pericyte
expression markers change when exposed to a TGF-β gradient; at low levels of
TGF-β, the pericyte expressed desmin and NG-2 as opposed to high levels of
TGF-β that induce the expression of α-SMA (50).
1.4

Mesenchymal stem cell

The fibroblast precursor is an adult stem cell known as the mesenchymal
stem/stromal cell (MSC) that retains the potential to differentiate into osteoblasts,
chondrocytes and adipocytes as well as many other tissues including neurons,
muscle, endothelium, and more (51). It is one of the stem cell populations of the
bone marrow, but can also be found as a resident stem cell population in most
tissues.
1.4.1 Characterization
MSC are easily isolated from tissues. In general, they are obtained from the
mononuclear fraction of a bone marrow aspirate and are selected for based on their
plastic adherence in tissue culture. A group of markers cell surface markers have
been used to characterize the cells, although there is no standard group of
phenotypic markers to completely encompass the MSC (52). We characterize our
human MSC by the positive expression of CD90, CD105, CD44, CD73, CD166 and
CD140b and the negative expression of the hematopoietic markers CD45 and
CD34, the endothelial marker CD31 and the macrophage marker CD11b. Murine
MSC can be obtained similarly to human MSC and can be prospectively isolated on
the positive expression of Sca1, CD105, CD106, CD44, and negative expression of
CD117 (c-kit), CD45 and Cd11b. For both human and murine MSC, no
7

standardized set of markers has yet to be agreed upon. However, the markers listed
above are the most generally agreed upon markers in the literature. Furthermore,
the expressions of specific surface marker combinations appear microenvironmentdependent, suggesting a strong tissue-specific-influence on the MSC phenotype.
1.4.2 Naïve origin and function
The MSC is a progenitor cell capable of generating several different connective
tissue cell lineages including bone, cartilage, muscle, fat and tendon. The primary
function of the cell is to repair injured tissues. Upon injury, the tissue elicits a
chemotactic inflammatory response to attract immune cells of various leukocyte
lineages and the MSC—a fibroblastic stromal repair cell that contributes to the
formation of granulation tissue through promoting angiogenic invasion to replenish
the oxygen and nutrient supply, and the fibroblasts and contractile cells
(myofibroblast) that help to close the wound (53).
Initially, the MSC was characterized as a bone marrow derived cell, consisting of a
mere 0.01% of the bone marrow cell population (54). More recently, the MSC has
been isolated from several other organs including adipose, umbilical cord, lung,
heart, brain and muscle tissue (55-59). Given that MSC have been found in several
tissues throughout the body suggests they play a significant role in maintaining the
population of cells that facilitates wound healing even as a minor cell population.
However, when confronted with an inflammatory incident, chronic or acute, MSC will
accumulate at the site of injury and provide growth factors, angiogenic factors and
structural support that include tissue reorganization and cell differentiation (3, 60).
Evidence of MSC accumulation is inflamed/injured environments have been shown
in models of myocardial infarction, ischemic brain tissue, injured lung tissue,
allograft rejection and SC incisions (61-66).
1.4.3 Tumor tropism
Just as injured tissue, the tumor elicits an inflammatory response that mimics that of
a wound. As stated by Dvorak and colleagues in the early 80s, tumors are “wounds
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that never heal” (67). Consequently, MSC respond to the tumor microenvironment
much in the same way they do a wound.
The migratory process that enables an MSC to migrate towards an inflamed
microenvironment such as the tumor is a lesser known process. Similar to the more
established leukocyte migration process, the MSC express many of the same
chemokine and cytokine receptors known to be involved in leukocyte migration.
Recent identification of chemotactic inducers, have implicated several chemokines,
SDF-1(68), CXCL8 (69), MCP-1 (70), Il-1β, and TNF-α (71) growth factors including
PDGF-A/B (72), IGF-1 (73) and TGF-β1 (71), components of the extracellular matrix
including fibronectin, vitronectin, and collagen I (74), and peptides such as LL-37
(Cathelicidin hCAP18) (75). Furthermore, chemokine receptors expressed by MSC
that have been implicated in the role of MSC migration include CCR2 in its role in
amplifying MSC tropism to breast tumors receiving low dose irradiation (76),
CXCR2 and CXCR4 in glioma tumor models expressing IL-8 and SDF-1,
respectively (77, 78)

In response to the chemotactic gradient from the tumor, the

MSC will promote a migratory response through the modulation of extracellular
proteases including the family of matrix metalloproteinases MMP-1, MMP-2, MMP13, TIMP-1 and TIMP-2 (79).
1.4.4 Function in pathogenic states
While the MSC facilitate the healing process of a wound, they also “facilitate the
healing” of a tumor which involves a repertoire of pro-growth, pro-angiogenic, and
structurally supportive functions. (Figure 1) Unfortunately, the hijacked function of
the MSC serves a pro-tumorigenic role in cancers. Investigators have shown the
MSC

in

the

tumor

microenvironment

participating

in

the

proliferation,

vascularization, and the metastatic/invasive state of the tumor cells (8).
As discussed by Kidd and colleagues in a 2008 review (3): there remains a debate
between investigators regarding the potential of MSC to inhibit (80-83) or enhance
(8, 84-87) tumor progression. The animal models currently used to assess the MSC
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potential may not accurately portray physiological conditions. Ultimately, the
pathogenic

potential

of

MSC

is

likely

dependent

on

microenvironment and each tumor microenvironment is unique.
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the

immediate

Figure 1. The tumor microenvironment. A heterogeneous composition of tumor
cell, immune cells, fibroblasts and endothelial cells that act in concert with one
another maintaining a supportive, pro-proliferative, pro-angiogenic, immunoevasive
environment. The chemotactic signature from a tumor microenvironment summons
the participation of additional cells like MSC for growth, support and sustenance.
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1.5

Tumor inflammatory profiles

Tumors elicit an inflammatory response analogous to that of a wounded
environment; this response includes peripheral cell migration, tissue remodeling,
cell proliferation and angiogenesis (67, 88). The tumor cell interaction with the
surrounding stroma provides a more drastic inflammatory signature that has been
implicated in the derivation and acquisition of additional stromal components from
both local and distant sources as well as a means for increased tumor
metastases/invasion potential. Investigators have identified factors including
chemokines such as CCL2, CCL3 and CCL5 (8, 89) that increase the migration
potential of both the contributing stroma and the tumor cells. Furthermore, it is
evident that amplification of inflammatory signals augments the stromal component
infiltration as seen by radiation (76), hypoxia (90) or Triterpenoid CDDO-Me (91)
treatment.
In addition to chemokines, glycosaminoglycans such as hyaluronan and
glycoproteins like osteopontin are associated with chronic inflammation and are
often present within the tumor microenvironment. Tumor associated fibroblasts from
hyaluronan overproducing mammary tumors have been isolated and transplanted
with tumor cells to show an increase in lymphangiogenesis in particularly in the
tumor-stromal interface in association with VEGF up regulation (92).
The chemotactic profile employed by the tumor will promote the incorporation of
local and distant cells that may be tumor suppressive or tumor promotive in nature
(3). The presence of these immune cells, fibroblasts and endothelial precursors in
the tumor microenvironment will further modify the chemotactic profile.
1.6

Glycoprotein CD44

CD44 is a class I transmembrane glycoprotein that has been shown to mediate cell
growth, survival, differentiation and migration (93). CD44 is a highly conserved gene
that has 12 alternatively spliced exons (94) that make up more than 100 splice
forms of the protein. The splice variability occurs in the extracellular portion of
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CD44. In addition to the splice variants, the post-translational modifications (e.g.
glycosylation) account for the discrepancies in CD44 expression between cell types
and local environments. The cytoplasmic tail of CD44 is known to interact with
components of the cytoskeleton including ankyrin and the ERM (ezrin, radixin and
moesin) proteins which are thought to regulate cell migration and shape (95-97).
The cytoplasmic tail also has an intracellular cleavage domain that has been shown
to translocate to the nucleus. Through association with Stat3 and p300 the CD44ICD has been shown to bind to promoter elements and influence transcriptional
regulation of target genes including Cyclin D1 (98). Furthermore, CD44 expression
has become well known as one of the markers of a “tumor initiating cell” particularly
in breast cancer, and is associated with drug resistance, apoptosis evasion and cell
survival (99-102).
1.6.1 CD44 ligands
Extracellular matrix proteins such as laminin, collagen, fibronectin, and hyaluronan
(HA) are able to bind to CD44 through docking sites in the extracellular region,
although the HA-binding domain is the only site that has been extensively mapped
(93). As the most well known CD44 ligand, HA functions as a mediator of the
inflammatory response and subsequent wound repair. In cancer, expression of HA
synthase has been associated with a pro-metastatic phenotype.
Osteopontin (OPN) is another known ligand of CD44 that has been implicated in
chronic inflammation. It is a secreted phosphoprotein produced by immune cells
and injured cells and is known to induce the motility of macrophages, neutrophils,
MSC, osteoclasts and tumor cells through association with CD44 and integrins
(95,103-106).
1.7

Migration

In a review on stem cell trafficking, Laird et al. discriminate the act of migration
described as an active phase of recruitment that is preceded by a passive phase of
circulation defined as homing (107). The migratory stimulation factors secreted by
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the tumor and its microenvironment selects for a population of circulating, or
“homing,” MSC. Given the large variability in the MSC population at the phenotypic
level, it is not surprising to discover that MSC are transient in nature and differ in
phenotype depending on the surrounding stimulus provided.
MSC are known to migrate towards sites of inflammation including wounds and
tumor microenvironments (66). Exogenously injected MSC have now been
extensively exploited as delivery vehicle for anti-cancer agents to tumors including
ovarian, glioma, lung, breast and Burkitt’s lymphoma tumor models (9, 91, 108111).
1.7.1 Chemokines, motogenic growth factors and peptides
In response to insult, inflamed environments secrete a variety of chemokines,
cytokines, growth and angiogenic factors and shed a large number of extracellular
matrix proteins. Tumor cells and the cells in the surrounding local tissue secrete
many chemokines and cytokines that mimic a wound response. Consequently, the
tumor microenvironment is under constant inflammation and is analogous to a
wound that does not heal (67). Chemokine profile from the tumor can be amplified
by adding insult such as radiation treatment which enhances the migration of MSC
to the environment (76).
CCL25 has been shown to induce the migration potential of MSC (112). SDF-1 is
produced by MSC under tumor stimulation and has been shown to modulate
migration through focal adhesion kinase and activation of Stat3 (68). In turn, Stat3
has a large number of downstream transcriptional targets implicated in regulation of
invasion (113). MCP-1 (CCL2) has been implicated in several tumor models to
modulate MSC migration (76, 78, 114).
Growth factors have also been implicated in the migration of MSC. PDGF-b has
been shown to play a role in the migration of MSC towards malignant gliomas (115).
EGF has been implicated in the migration of keratinocytes (116) and breast cancer
cells (117).
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In a tumor microenvironment, tissue remodeling is constantly taking place.
Throughout this process, a large amount of cellular debris is accumulated, this
debris is often cleaved extracellular matrixes and other peptides, proteoglycans and
glycoconjugates. These elements can induce an inflammatory response, but they
are also capable of binding and presenting chemokines and growth factors. Such
elements include the CD44 ligands, osteopontin (118) and hyaluronic acid (119). A
peptide fragment of the anti-microbial protein, LL-37, is over-expressed in ovarian,
breast and lung cancers and has been shown to facilitate MSC migration towards
tumor cells (120).
1.7.2 Cell signaling pathways
Cellular migration is an intricate mechanistic process much like a Rube Goldberg
machine. Multiple receptors can be stimulated/activated to induce the same
physiological outcome—cellular migration. The chemotactic factors eluded to in the
previous section have corresponding receptors on the cell surface of MSC. There
are several different receptors implicated in the migration of MSC from G-coupled
protein receptors to tyrosine kinase receptors to integrins. By blocking endogenous
HA from binding to and activating CD44, the activation of several receptor tyrosine
kinases can be inhibited including ERBB2, EGFR, IGF1Rβ, c-MET, and PDGFRβ
(121, 122).
Migration is a polarized process sustained by a series of signals to the leading and
lagging edges of the cytoskeleton. CD44 has been implicated in the signaling
pathways of migration as an intermediary in the activation of non receptor tyrosine
kinases (e.g. Src family) (123).
In a recent paper, one of the CD44 variants is shown to stabilize androgen receptor
activation through complex interaction with cMet upon HGF and hyaluronan
activation of cMet and CD44, respectively (124). Furthermore, using a renal cell
carcinoma line model, CD44 was shown to activate Stat3, complex with the
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acetyltransferase, p300 and by ChIP sequencing was shown to bind 19 different
promoter elements including Cyclin D1 (98). Furthermore, Lee et al confirmed that
CD44 was able to mediate expression of other Stat3 responsive gene targets
including VEGF and MMP2 (98).

Moreover, the Stat3 transcription factor is

associated with migration/invasive phenotype of tumor cells through the
transcriptional activation of genes such as Twist (113, 116, 125-127).
Twist has been described as a “master regulator” in embryonic development as it
plays a crucial role in the epithelial to mesenchymal transition of mesoderm
formation (128) and neural crest development (129). More recently, Twist has been
implicated in tumor EMT and is associated with cell invasiveness. (130)
1.8

MSC and anti-tumor gene therapy

Targeted gene therapy/drug delivery is an appealing treatment tool because of the
potential avoidance of toxic side-effects to normal tissues. With a targeted delivery
system, many factors that impede drug efficacy including the pharmacokinetics and
pharmacodynamics can be improved. Localizing the site of drug activity to the
targeted tumor using a delivery vehicle can enhance the anti-tumor effect as well as
the non-specific toxicity to normal tissues.
While other cell types have been reported to display tumor tropism (10, 20, 45),
MSC are arguably better suited as a targeted gene therapy delivery tool. First, MSC
are as easily accessible from bone marrow and liposuction aspirates. They readily
propagate in vitro. Furthermore, ex vivo expanded MSC retain their tumor homing
potential. Finally, MSC can be easily gene modified because they possess the
metabolic activity and molecular machinery for sufficient production of therapeutic
gene products (9, 131).
Studeny et al first reported the efficacy of the MSC as a delivery vehicle in the
delivery of interferon beta in the treatment of melanoma (9). Since this initial report,
several investigators have showed the targeted migration and engraftment of MSC
to the tumor model and furthermore reported an efficacious anti-tumor effect using
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biological proteins including interferon alpha (132), IL7 (133), IL12 (134) and TRAIL
(135). MSC have also been used to deliver molecular antagonists against
hepatocyte growth factor (109), urokinase-type plasminogen (136), and truncated
soluble vascular endothelial growth factor decoy receptor (110, 137). Furthermore,
MSC expressing pro-drug converting enzymes (cytosine deaminase and HSVthymidine kinase) have also been delivered to the tumor microenvironment to
enhance the anti-tumor therapy (138-140).
MSC have already shown great potential as a tumor-targeted delivery vehicle, but
therapeutic efficacy may be enhanced by genetic manipulations of MSC to further
improve target potential. This has been achieved in a myocardial infarction model
where MSC modified to over express the surface receptor CXCR4 were better able
to target and home to the infracted region (141). The potential to modify MSC for
enhanced tumor-tropic migration rate is a foreseeable stride in the effort to achieve
an unparalleled anti-tumor delivery vector.
1.9

Objectives and Hypothesis

Despite the migratory propensity of the MSC for site of inflammation like the tumor
microenvironment, the potential of an exogenously injected population of MSC to
reach the tumor target is less than 15%. The efficacy of MSC as a delivery vehicle
could be greatly improved if the mechanism of migration were elucidated, and could
subsequently be exploited to enhance tumor-specific migration. Like every
treatment, there are benefits and adverse effects. Investigators have reported both
pro- and anti-tumorigenic effects of MSC on tumor growth and progression.
Understanding the potential long term effect of the MSC on the tumor
microenvironment is important to the prospect of MSC as therapeutic delivery
vehicles. Furthermore, understanding the MSC in the context of the tumor
microenvironment may elucidate on the role of the endogenous MSC in tumor
development as a precursor of stroma.
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The objective of this study was to elucidate characteristics of the tumor stroma
participants, particularly of the bone marrow derived MSC. Therefore, we
hypothesized that intracellular signaling via CD44 mediates the migration and
incorporation of mesenchymal stem cells to the tumor microenvironment. To
investigate this hypothesis we proposed the following specific aims:
Aim I: To identify the MSC receptor(s) responsible for the migration of this
stromal cell to the tumor microenvironment.
Primary human MSC were analyzed for the chemokine ligand and receptor
expression changes under the influence of tumor conditioned medium revealing
CD44 receptor. Migration of MSC toward tumor conditioned media was inhibited in
vitro and in vivo. Mechanistic data revealed that tumor stimulated MSC can activate
Twist expression leading to increased migration.
AIM II: Elucidate the stromal contribution of the MSC to the tumor
microenvironment as tumor associated fibroblasts in the context of MSC
expressed CD44
MSC admixed with tumor cells and engrafted in vivo show enhanced tumor growth
through angiogenic and structural support in the form of tumor/carcinoma
associated fibroblasts (TAF/CAF) as identified by surface markers. Utilizing
transgenic CD44 knockout mice, a series of tumor engrafting studies were carried
out with both endogenous and exogenous bone marrow derived stromal
populations. Harvested tumors were analyzed for size as well as TAF markers and
angiogenesis. We determined that MSC expressed CD44 is necessary for efficient
TAF support within the tumor microenvironment. Furthermore, we confirmed that
CD44KO bone marrow derived cells are less capable of tumor contributing to
FAP+/FSP+ tumor development but that host derived WT stromal tissues
compensate for the deficient FAP+/FSP+ TAF population within the tumor.
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2.0 Materials and Methods
2.1 Cell culture
Murine E0771 breast cancer cells were generously donated by Dr. F.M. Sirontak of
the Memorial Sloan-Kettering Cancer Center in New York, New York. Murine 4T1
cells were stably transduced with a lentivirus expressing renilla luciferase (4T1rLuc) and donated by Dr. J. Ling of MD Anderson Cancer Center. Tumor cell lines
including PANC-1, Skov-3, MDA-468, MCF7, MDA-231 cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA). MDA-231 and Skov-3
cells were maintained in alpha-minimum essential medium (α-MEM; HyClone,
Waltham, MA), containing 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA),
sodium pyruvate, nonessential amino acids, vitamin solution (Life Technologies,
Grand Island, NY), L-glutamine (Gibco/Invitrogen, Carlsbad, CA) and penicillinstreptomycin (Gibco/Invitrogen, Carlsbad, CA). E0771 and 4T1 cells were
maintained in Roswell Park Memorial Institute medium (RPMI-1640; HyClone,
Waltham, MA) supplemented with 10% FBS, penicillin–streptomycin and Lglutamine. Finally, PANC-1, MDA-468 and MCF7 cells were maintained in
Dulbelcco’s modified eagle medium (DMEM, HyClone, Waltham, MA).

Tumor

conditioned media was made by incubating 30-80% confluent cells in 2% αMEM for
48 hours.
2.2 Isolation and propagation of MSC
2.2.1 Human MSC
Human MSC (hMSC) were obtained from bone marrow aspirates of normal donors
undergoing bone marrow harvest for allogeneic bone marrow transplantation upon
informed consent, according to institutional guidelines under the approved protocol,
as described previously (9). Following a Ficoll-Hypaque density gradient (Sigma, St.
Louis, Mo) and mononuclear cells were re-suspended in MSC medium: α-MEM,
20% FBS, L-glutamine and penicillin-streptomycin. The suspension was plated in 10
ml MSC medium in a 180 cm2 dish. Non-adherent cells were removed three days
after culture establishment and the adherent layer was washed with phosphate
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buffered saline (PBS) before the MSC medium was replaced. Adherent monolayers
were cultured until they reached 80-90% confluence, at which time they were
trypsinized (0.25% trypsin/0.1% EDTA; Gibco/Invitrogen, Carlsbad, CA) and subcultured at 5,000-6,000 cells/cm2. MSC media was replaced every three days. Cells
were used for experimental procedures at passages 3-5.
2.2.2 Murine MSC
Murine MSC (mMSC) were isolated as described previously (142). Femurs, tibias,
and iliac crests were isolated from 6-10 week old mice. Muscle and connective
tissue was removed from bones with scalpel and the bone were crushed with a
mortar and pestle in PBS containing 2% FBS to release the marrow. The marrow
was collected and stored in MSC medium in a 10cm dish. The crushed bones were
further diced with a scalpel and suspended in 3mg/ml Collagenase Type I
(Worthington Biochemical Corporation, Lakewood, NJ) using 2 ml/mouse. The
suspension was placed in a 37°C shaker at 300 rpm for 45 minutes. After
incubation, bones were filtered out and cells were washed in PBS. Cells from the
bone were combined with those plated from the marrow in MSC medium in a 10cm
dish according to the same procedure used for hMSC culture. Cell density was
maintained between 2,000 and 6,000 cells/cm2.
2.3 Differentiation assays
2.3.1 Osteoblast differentiation
22,500 hMSC or mMSC were plated sub-confluently in a 12 well plate in NH
OsteoDiff Medium (Miltenyi Biotec, Auburn, CA) and cultured for 3 weeks with twice
weekly media replacement. After 3 weeks, osteoblasts were fixed with pre-cooled
100% methanol and then washed with PBS. Cells in each well were stained with
either chromogenic alkaline phosphatase substrate, SIGMA FAST BCIP/NBT
(Sigma Aldrich, St. Louis, MO) incubated at 37° for 10 minutes, or with Alizarin Red
S solution (Sigma Aldrich, St. Louis, MO) for calcium staining. Alizarin Red S
solution was added to washed cells and incubated at room temperature for 10
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minutes. All wells were then washed with water and osteoblasts were visualized and
photographed on an Olympus BX41 microscope (Olympus, Center Valley, PA).
2.3.2 Adipocyte differentiation
20,000 hMSC or mMSC were plated in a 12 well plate in 20% αMEM. After the cells
reached confluence they were maintained in adiopogenic induction medium for 4872 hours (DMEM, 10%FBS, penicillin, streptomycin, L-glutamine, 10 μg/ml insulin,
500 μM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 200 μM
indomethacin (last four chemicals purchased from Sigma Aldrich)). After 72 hours,
cell media was changed to adipogenic maintenance medium (DMEM, 10%FBS,
penicillin, streptomycin, L-glutamine, and 10 μg/ml insulin) for 24 hours. The round
of 72 hour induction followed by 24 hour maintenance was repeated for three
rounds. After the third round, cultures were maintained in adipogenic maintenance
medium for 10 more days with twice weekly media changes. Adipocytes were then
visualized by staining with Oil Red O (Sigma). Cultures were fixed in 10% formalin.
After one hour, formalin was washed off with 60% isopropanol, and cultures were
dried. Twice filtered (0.22 μm syringe filter) Oil Red O working solution (4 ml water +
6 ml of 0.35% Oil Red O dissolved in 100% isopropanol) was placed on dry
adipocytes for 10 minutes. Cells were washed with water and let dry. Red stained
lipid vacuoles were then visualized and photographed within adipocytes on the
Olympus BX41 microscope.
2.3.3 Chondrocyte differentiation
350,000 cells were pelleted in a 15 ml polypropylene Falcon tube. Cells were
resuspended in chondrocyte differentiation medium consisting of DMEM, penicillin,
streptomycin, L-glutamine, 50 μg/ml ascorbic acid, 100nM dexamethasone, and
10ng/ml transforming growth factor β3 (TGF-β3). The suspension was pelleted
again and placed into 37⁰C incubator with the cap on but loosened for gas
exchange. Without disturbing the pellet, the chondrocyte differentiation medium was
replaced 3 times a week. 10ng/ml TGF-β3 was added daily. The pellets were
cultured for 21 days, before they were rinsed in PBS and fixed in 10% formalin.
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They were then paraffin embedded and sectioned for histology. Sections were
deparaffinized

in

xylene

and

rehydrated

in

a

series

of

alcohols.

Mucopolysaccharides associated with chondroblast differentiation were stained with
1% Alcian Blue in 5% acetic acid for 30 minutes. After rinsing with tap water and
distilled water, sections were counterstained with Nuclear Fast Red (Lab Vision
Corporation, Fremont, CA) and mounted in aqueous mounting medium. Sections
were visualized and photographed on the Olympus BX41 microscope.
2.3.4 CFU-F assay
5

5x10 whole Bone marrow cells were plated in MSC medium in a 12 well dish.
Medium was changed twice per week for 2 weeks. Wells were then washed with
PBS and fixed in ice cold methanol. Giemsa staining solution was applied to fixed
wells for 10 minutes. Wells are washed with water and then imaged.
2.4 Flow cytometry
For analysis, cells were trypsinized, washed and resuspended in ice cold PBS
supplemented with 2% FBS and 1% BSA (106 cells/100μl/staining reaction). 1μg of
each antibody was added to the cell suspension and incubated at 4°C for 30
minutes.

Cells were washed two times in PBS and resuspended in 250μl for

analysis or 100μl for secondary antibody staining (PE-secondary antibody for 15
minutes on ice). Cells were washed two more times before being resuspended in
250μl of PBS on ice for analysis on a BD LSRII Flow Cytometer (Becton Dickenson,
San Jose, CA) with FACS Diva software (MDACC Core Flow Cytometry Facility) or
on a Beckman Coulter Gallios with Kaluza Software (Beckman-Coulter). Human
antibodies utilized for flow cytometry included: CD105, CD90, CD140b, CD73,
CD116, CD146, CD44, CD31, and CD34 (BD Bioscience, San Jose, CA).
Antibodies for mouse antigens included: Sca-1, CD11b, CD31, CD34, CD44,
CD106, CD140b, CD45 and c-kit (eBiosciences, San Diego, CA).
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2.5 Fluorescence activated cell sorting (FACS)
Cells were sorted based on GFP expression. Cells were trypsinized, washed,
filtered and resuspended in ice cold PBS supplemented with 2% FBS. Cells were
sorted into GFP+ and GFP– sub-populations (BDFACS Aria).
2.6 Migration assays
2.6.1 Transwell assay
MSC migration was assayed using 8μm pore, 6.5mm transwell inserts in a 24 well
plate. The 18hr serum-starved MSC were plated at 4x104 cells per well, with tumor
cell conditioned media, serum media, or serum free media. For migration inhibition,
MSC were pre-incubated with neutralizing antibodies for 45 minutes prior to plating.
MMP inhibititor V (cat#444285) was purchased from EMD Chemicals (Gibbstown,
NJ) After 24 hours, the media was removed, the cells were fixed, stained and
excess cells were wiped from the top layer of the transwell insert and inserts were
dried overnight. Only the cells within the membrane were analyzed using a 3 step
staining method (Fisher Scientific, Pittsburgh, PA) comparable to the WrightGiemsa method. Manual cell counts and images were captured (Olympus BX41
microscope with an Olympus DP70 camera attachment), and followed by a
quantitative analysis measuring the amount of staining on each membrane. The
transwell membranes were placed in 300μl 2% deoxycholic acid until dye was fully
solubilized (3-8 hours).
quantitative

A fixed wavelength of 595nm was used to obtain a

measurement

from

each

sample

(Beckman

Du

640

Spectrophotometer).
2.6.2 Scratch assay
MSC were grown to a confluent monolayer in a 12 or 24 well dish. Using a p200
pipette tip a 5mm long “scratch” was made along the bottom of the dish. The
location of the scratch was referenced on the dish—but outside of the field of view
on the microscope.
The wells were gently rinsed with serum media to clean the edges of the scratch
and discard debris. 1% serum MSC media was added to the wells as base media.
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Neutralizing antibody, full serum, IgG antibody, small molecule inhibitors or tumor
conditioned media was added to sample wells. Cells were incubated at 37ºC.
Images were acquired on a fluorescence or phase contrast microscope at select
time points over the duration of the incubation—every 60 minutes over a 48 hour
period. Using image analysis software, the distances between the scratch and the
migrating cells can be quantitatively compared using Slidebook, Image Pro-Plus
software (Media Cybernetics) or a freeware (http://rsb.info.nih.gov/ij/).
2.7 Tube formation assay
HUVEC (ATCC, Manassas, VA) were cultured in EGM2 (Clonetics, Workingham,
UK). 3x104 HUVEC were plated per well into a 24 well plate in triplicate. Media was
replaced 12 hours later with MSC conditioned media. Wells were imaged and
analyzed with an Olympus Ix81 microscope with a DSU confocal attachment and
Slidebook software (Center Valley, PA). 4 images were taken per well, tubes were
manually counted and averaged between groups.
2.8 Western blot
Cells were lysed in protein lysis buffer (50mM HEPES (238.3g/mol), 300mM NaCl
(58.4 g/mol), 2mM EDTA (372.24 g/mol), 50mM NaF (41.99 g/mol), 2mM Sodium
Orthovandate (183.91 g/mol), 10% (v/v) glycerol, 2% (v/v) NP40, 1% (v/v) Triton X100 and a cocktail of protease and phosphatase inhibitors). After 1-2 hours on ice,
lysates were spun down for 30 min at 13,000rpm, lysate supernatant was quantified
by Bradford assay (Bio-Rad, Hercules, CA) and then lysate was boiled with loading
buffer and loaded onto a 12% SDS-PAGE gel (Bio-Rad, Hercules, CA). After
electrophoresis, proteins were transferred onto Hybond-P membranes (Amersham
Pharmacia Biotech), or nitrocellulose odyssey membranes (Licor Biosciences,
Lincoln, NE) followed by immunoblotting. Signals were detected using ECL-Plus
(Bio-Rad, Hercules, CA), alternatively, if fluorophore-conjugated secondaries were
used the immunoblot signals were detected on the Odyssey infrared imaging
system (Licor Biosciences, Lincoln, NE).
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2.9 Chromatin Immunoprecipitation assay (ChIP)
1x107 MSC were grown to 80% confluency in 15cm plates. Cells were subjected to
Skov-3 conditioned media before being fixed in 1% formaldehyde for 10 minutes at
room temperature. Glycine (125mM final concentration) was added to stop the
cross-linking reaction. After PBS wash, cells were scraped in PBS+protease
inhibitor cocktail and centrifuged (650xg for 5 min). Cells were resuspended in lysis
buffer and protocol was continued according to manufacturer’s details (GA-101
ChampionChIP, SABiosciences, Frederick, MD). Briefly, chromatin was sheared on
ice and then pre-cleared. Fractions were immunoprecipitated including negative and
positive controls as well as CD44 (ab65829; Abcam, Cambridge, MA). Twist
promoter primers listed in Table 1.
2.10 Immunocytochemistry
200 MSC per well were plated in an 8-well chamber slide (Lab-Tek, Naperville, IL).
Cells were subjected to 24 hours of serum free media before conditioning with
tumor conditioned media (Skov-3, MDA-231, or PANC-1) or MMP inhibitor V
(444285; EMD Chemicals, Gibbstown, NJ) or small chain hyaluronan oligomer
(100µg/mL of oHA from Dr. B. Toole) for 24 hours. After conditioning, cells were
fixed in 3% formaldehyde, blocked in 3% BSA and stained with primary (listed in
flow section) antibody at 4°C overnight. Secondary antibodies, Alexafluor® 488,
Alexafluor® 594 or Alexafluor® 647 (Molecular Probes, Carlsbad, CA), were used at
a 1:1000 dilution for 8 hours at 4°C or 1 hour at room temperature. 5 mg/ml DAPI
(Sigma, St. Louis, MO) stain was used at a dilution of 1:10,000 for 1 minute. Glass
coverslip was applied over Dako Fluorescent Mounting Media (Dako, Denmark) and
let dry in the dark before edges were sealed with nail hardener. Image analysis was
performed using an Olympus Ix81 microscope with aDSU confocal attachment and
Slidebook software (Center Valley, PA).
2.11 Immunohistochemistry
Tissue sections were deparaffinized in a series of xylene and ethanol gradient
incubations before subjected to incubation in boiling sodium citrate solution. Tissue
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sections were stained with CSA II IHC kit (Dako, Denmark). Briefly, sections were
blocked in peroxidase for 5 minutes, before being washed and blocked with a
species specific protein block. Primary antibody was added for 15 minutes followed
by 3x wash. Anti-mouse (or species secondary in use) IgG-HRP was added for 15
minutes followed by 3x wash. For low expressing proteins, an amplification reagent
was used prior to anti-fluorescein HRP followed by DAB chromagen substrate.
Slides with counterstained with hematoxyalin stain (Dako, Denmark) before being
dehydrated in a series of ethanol incubations and then were finally cover-slipped
with working oil mounting media.
2.12 Immunofluorescence
Paraffin embedded tissue sections were deparaffinized in a series of xylene and
ethanol gradient incubations before subjected to incubation in boiling sodium citrate
solution. Frozen tissue sections were fixed in ice cold acetone for 10 minutes,
rinsed in PBS and then incubated in blocking buffer (3%FBS, 1%BSA and 3% goat
serum) for 1 hour at room temperature. Primary antibody was added at optimal
dilution in diluted blocking buffer overnight at 4ºC. Slides were washed three times
in PBS with 0.05% Tween-20 (PBST). Secondary Alexafluor antibody was added at
a 1:1000 dilution in diluted blocking buffer and placed on the slide for 1 hour at room
temperature. Slides were washed three times in PBST before being stained with the
nuclear marker 5mg/mL DAPI at a 1:10,000 dilution for 1 minute. Slides were
washed three more times in PBST, and covered with glass coverslip over Dako
Fluorescent Mounting Media (Dako, Denmark) and left to dry in the dark before
edges were sealed with nail hardener. Multispectral images were obtained using a
CRi attachment on an Olympus Ix81 microscope with a DSU confocal attachment
using Nuance software, and images were analyzed using InForm software (CRi,
Woburn, MA).
Data analysis was performed with Inform software. Briefly, regions of interest were
defined on 4 images, and the recognition software was trained to classify all images
based on stroma versus parenchyma versus background. Then, based on DAPI
26

fluorescence, the nuclei were defined and classified followed by cytoplasm definition
surrounding each defined nuclei. Fluorescence data (pixels) was quantified for each
nucleus and cytoplasm for every cell in every image. Nuclear and cytoplasmic pixel
signals exported and summated to give per cell quantitation of pixel count for each
fluorochrome per cell (nucleus+cytoplasm). Numerical cutoffs based on isotype
controls were used to define combination of either Alexa Fluor 488+ or Alexa Fluor
594+ cell populations. Each image was evaluated on a percent positive basis. 10
images per slide were quantified and averaged at 3 different depths within the
tissue section which were in turn averaged to give a final percent across each
tumor. 3 tissue sections were analyzed in this manner per experimental group.
2.13 Molecular analysis
All cells subject to PCR analysis were extracted with either DNAeasy or RNAeasy
kits (Qiagen, Valencia, CA) according to manufacturer’s protocol. Nucleic acid
concentration was measured using Nanodrop 2000c (ThermoScientific, Wilmington,
DE). DNA was used at 0.25µg per reaction and RNA was used at 1µg per reverse
transcription reaction.
2.13.1 PCR
Maxima Hot Start 10x buffer, 25mM MgCl2, 25mM dNTP and 5U Taq was
purchased from Fermentas Life Sciences (Glen Burnie, MD). Primers purchased
from Integrated DNA Technologies (Coralville, IA) were prepared into 10µM stock
solutions and are listed in Table 1.
2.13.2 RT-PCR
Inflammatory chemokine and cytokine arrays were purchased from SA Biosciences
(Frederick, MD). After 24 hour conditioning, RNA was collected (RNAeasy; Qiagen,
Valencia, CA) and reverse transcribed using cDNA kit (SABiosciences, Frederick,
MD). Data was analyzed using SABiosciences spreadsheet to calculate fold change
based on delta Ct.
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For all other RT-PCR, 1µg RNA was reverse transcribed using a kit from Signalway
Biotechnology (Pearland, TX). 20µL of cDNA was diluted with 100µL of distilled
RNAse/DNase free water. Sybr-green master mix was purchased from Applied
Biosystems. 0.5µL-1.0µL cDNA was used per reaction on an assay dependent
basis. 0.5µL forward and reverse primer (both at 10µM stocks) 10µL distilled water
and 12µL Sybr-green master mix was added per well for a total volume of 25µL. All
reactions were done in triplicate and carried out in a 96well fast plate in an
ABI7900HT

Thermocycler

(Applied

Biosystems).

Relative

expression

was

calculated by normalizing samples to GAPDH (human) or 18s (murine) and then
compared between control and sample sets using the delta-delta Ct method. All
data is presented as fold change over control (2-ΔΔCt).
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Table 1. Primers
Protocol name

Primer name

sequence (5'‐‐>3')

CD44-Twist ChIP proximal

Twist prox prom F

CGG GGG AGG GGG ACT GGA AAG C

Twist Prox prom R

AGG CCT CCT GGA AAC GGT GCC G

Twist Dist prom F

TAC TCC AGC GCG GTG CAC AAA ACT

Twist Dist prom R

AAC GAA GAG CCC CAA AGA GGG TGT

CD44 promoter F

AGG GCT CTG AAG ATA GCG CCA GG

CD44 promoter R

AAT GCA CCC AGC CAT CCC CCT

CD44 F open

GGG AGC TGG GAC ACT TAA CA

CD44 R open

GGG CCC TAA TTT CAG AAA GC

Twist RT F

GGA GTC CGC AGT CTT ACG AG

Twist RT R

TCT GGA GGA CCT GGT AGA GG

VegfA F

CTT GCC TTG CTG CTC TAC C

VegfA R

CAC ACA GGA TGG CTT GAA G

VegfC F

TGC CGA TGC ATG TCT AAA CT

VegfC R

TGA ACA GGT CTC TTC ATC CAG C

EGF F

CCT GCC TAG TCT GCG TCT TT

EGF R

CAC AAT ACC CAG AGC GAA CA

IL-8 F

ATG ACT TCC AAG CTG GCC GTG GCT

IL-8 R

TCT CAG CCC TCT TCA AAA ACT TCT C

OPN F

GCC AGT TGC AGC CTT CTC A

OPN R

GCA AAA GCA AAT CAC TGC AAT T

CD44-Twist ChIP distal
CD44-CD44 ChIP promoter
CD44 expression
Twist expression
VegfA expression
VegfC expression
EGF expression
IL-8 expression
OPN expression
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2.14Transfections
Transfections were carried out using JetPrime reagent (VWR, West Chester, PA) or
Amaxa electroporation (Lonza Biotech, Walkersville, MD). Lentiviral transduction
was done using BES transfection buffer (1.5mL of 2x BES: 50mM BES, 280mM
NaCl, 1.5mM Na2HPO4 in water at 6.96pH) with 150µL of 2.5M CaCl2 with 10µg
DNA plasmid, 10µg pPax and 10µg pMD2 plasmids in 1.35mL distilled water.
Solution was aerated for 30 seconds using 5mL pipettaid/tip before being added to
fresh 10mL DMEM supplemented with 10% FBS and 10% PSG on HEK-293T.
2.14.1 siRNA
siRNA CD44 and negative control #1 siRNA purchased from Ambion (Austin, TX).
siRNA was transfected into MSC using JetPrime Transfection reagent as per
manufactures instruction (VWR, West Chester, PA) After 48 hours, cells were
subjected to assay of choice
2.14.2 Luciferase reporter assay
The CD44 PGL3 luciferase promoter construct was obtained from Addgene
(Cambridge, MA). Luciferase assay was performed in a 96 well plate according to
manufactures instructions (Promega, Madison, WI). Tumor conditioned media was
obtained from tumor cell lines grown for 2 days at 50-80% confluency and filtered
through a 0.2µm syringe filter to remove cell debris. MSC in a 96 well plate (1x104
cells/well) were conditioned with the media for 1, 12 and 24 hours. MSC
proliferation was measured after 12, 24 and 36 hours following breast cancer
conditioning using CyQuant Proliferation assay protocol (Molecular Probes,
Carlsbad, CA).
2.15 Viral transduction
2.15.1 Adenoviral vectors
Soluble CD44 Adenoviral vector was obtained from Dr. B. Toole, amplified in 293T
cells, and concentrated in a cesium chloride gradient. Firefly luciferase and renilla
luciferase constructs were made in house. A recombinant adenoviral (Ad) vector
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expressing firefly luciferase (ffLuc) or renilla luciferase (rluc) possessing an RGDmodified fiber (AdLuc-F/RGD) was prepared, purified, and titered as described
previously (143). Adenoviral transductions of cell lines were carried out using a cellspecific multiplicity of infection (MOI) in serum free medium when cells were 70%
confluent. Human MSC were incubated with AdLuc/RGD at 3,000 MOI for 4 hours,
C57bl/6 MSC were incubated with AdLuc/RGD at 5,000 vp/cells for 6 hours in
serum-free medium and tumor cells were incubated with AdLuc/RGD at 3,000 MOI
for 6 hours in serum-free medium. After incubation serum containing media was
added to the culture. Transduction efficiency was routinely above 95%, as
previously reported (143). MSC were assessed for luciferase expression by plating
increasing numbers of transduced cells into 96 well plates and adding 1μl of
substrate solution (Caliper Life Sciences [Xenogen], Hopkinton, MA) per well
containing media. 30 sec later cells were placed into the imager for detection. A
standard curve could be generated between the number of cells plated and the
photon count per well detected by the IVIS imager. ffLuc labeled MSC were also
assayed for maintenance of adipogenic, osteogenic and chondrogenic potentials as
described above.
2.15.2 Lentiviral vectors
Five

GIPZ

shRNA

(clone

ID:

1-V2LHS_111680;

2-V2LHS_111682;

3-

V2LHS_111684; 4-V3LHS_334831; 5-V3LHS_334830) lentiviral constructs against
CD44 and one negative control shRNA (RHS4346) (Open Biosystems, Huntsville,
AL) were transfected into HEK-293T cells with pPax and pMD2 plasmids using
JetPrime Transfection reagent or BES. Supernatants were collected and filtered
after 72 hours and a subsequent 48 hours thereafter for a total of 40mL. Virus was
concentrated in 8.5% polyethylene glycol (8.4mL PEG- from 50% stock solution)
and 0.3M sodium chloride (3.75mL NaCl- from 4M stock solution) and balanced with
PBS to equal volume. Solution was placed on a shaker at 4⁰C for 90 minutes.
Solution was spun down at 4⁰C at for 45minutes. Pellet was resuspended in 300μl
PBS, snap frozen and stored at -80⁰C. For transduction, 20ul of each concentrate
were combined with 5ul of 5mg/ml polybrene stock in 10mL of fresh 20% serum
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media. Media was changed 24 hours post transduction. Cells were sorted by FACS
for GFP positivity.
ffLuc/cGFP co-expressing vector was made by subcloning the ffLuc from
pGL4.51[luc2/CMV/Neo] Vector (Promega, Madison, WI) into pCDH-CMV-MCSEF1-copGFP_CD511B-1 (System Biosciences, Mountain View, CA).
2.16 Animals
C57Bl/6 mice expressing either GFP under the control of the ubiquitin promoter,
tdTomato under the control of the ROSA26 promoter, or CD44 KO mice expressing
LacZ under the CD44 promoter were purchased from Jackson Labs, and bred in
house to maintain colonies. Additionally, severe combined immune disorder (SCID)
mice were purchased from Jackson Lab (NOD.CB17-Prkdcscid/J; Bar Harbor,
ME). All mice were housed in accordance with institutional standards, and treated
under approved protocols. Mice were allowed food and water ad libum and in
accordance to the facility were healthy and free of opportunistic organisms.

2.16.1 Exogenous MSC migration study
SCID mice were anesthetized and then injected SC with 5x105 rLuc labeled Skov-3
cells suspended in 100μL of PBS into both hind limbs. Mice were divided into 4
groups (n=20), all receiving rLuc-Skov-3 tumor cells.

Tumor engraftment was

confirmed by bioluminescent imaging (IVIS-Xenogen 100 system; Caliper
Lifesciences, Hopkinton, MA) 56 days post injection. Confirmation of engraftment
was followed by tail vein injections of 1x106 ffLuc labeled MSC; mice received either
normal MSC (black and blue groups) or MSC expressing the soluble CD44
adenovirus (green and red groups).

The blue and red groups received an

intratumoral injection of the soluble CD44 expressing adenovirus (heretofore known
as, Ad-s44) in the right limb 48 hours prior to IV MSC administration.
Bioluminescent imaging was conducted for 5 consecutive days post MSC
administration. Images were acquired over a 3 minute period to detect and quantify
the ffLuc expression (MSC) and 2 minute for rLuc expression (tumors).

32

2.16.2 Tumor growth study
Wild type and transgenic CD44 knockout (Jackson Laboratory, Bar Harbor, ME)
murine MSC were isolated as previously described (66) and stably labeled with
GFP-lentivirus. 1x106 MSC were admixed with 1x106 4T1 tumor cells and injected
into the mammary fat pad of SCID mice. 3 weeks following injection, mice were
sacrificed and tumors and organs removed for immunohistochemical analysis.
2.16.3 Bone marrow transplantation study
Ubiquitous-expressing DS-Red C57/B6 wild type and transgenic CD44 knockout
(Jackson Laboratory, Bar Harbor, ME) murine bone marrow were isolated as
previously described (142). 2x106 total bone marrow cells were tail vein injected into
lethally irradiated ubiquitously expressing GFP C57/B6 mice. Recipient mice (n=10)
received either tdTomato bone marrow (n=5) or CD44 KO bone marrow (n=5), one
mouse received PBS injection as control for lethal radiation dose. The control
mouse died at day 18. At day 24, mice were bled and transplant was confirmed by
flow. Day 25, the right dorsal side of anesthetized recipient mice was shaved and
cleaned with alcohol. Then, 2x105 EO771 tumor cells suspended in 50μl of PBS
were injected adjacent to the fat transplant site. Following 29 days of tumor
engraftment, mice were sacrificed and tumors and organs removed and placed in
formalin or snap frozen in OCT compound for subsequent immunohistochemistry or
immunofluorescent staining.
2.17 Bioluminescent imaging
Images were captured using Xenogen’s IVIS 200 system and Living Image
Software (Caliper LifeSciences, Hopkinton, MA). The ffLuc substrate, d-Luciferin
(100μL of 4mg/mL in PBS; Biosynth International Inc, Itasca, IL) was injected IP 5
minutes prior to imaging. The rLuc substrate, coelenterazine (Biotium, Inc.,
Hayward, CA) was resuspended and diluted in PBS injected IP 5 minutes prior to
imaging.

Bioluminescent images were acquired between a 10 second and 10

minute period to detect and quantify the ffLuc or rLuc expression depending on the
expression system and the place of signal within the animal.
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Analysis of the

bioluminescent imaging was carried out by creating a standard region of interest
(ROI) around the right and left hind legs to calculate the flux (photons per second;
p/s) of the target signal in the given area.

Relative quantification of the MSC

number and tumor size were then calculated by normalizing the MSC flux against
the tumor flux in order to achieve a comparable number of migrated MSC toward
each tumor individually. Statistical significance was determined by the Student’s Ttest.
2.18 Statistical Analysis
Numerical data were expressed as means ± standard error. Statistical differences
between the means for the different groups were evaluated with Prism 4.0
(GraphPad software) using either the Student’s T-test or analysis of variance
(ANOVA), with the level of significance at p < 0.05 with the exception of the bone
barrow transplant experiment where significance was set at p<0.1.
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3. Results
3.1 Characterization of MSC
MSC were isolated, expanded and characterized by passage three by surface
marker expression by flow cytometry and by differentiation capabilities into
adipocytes, osteoblasts and chondrocytes.
Human MSC were characterized based on the positive expression of CD90, CD105,
CD44, CD73, CD140b, CD146 and CD166, and the negative expression of
hematopoietic marker CD45, endothelial markers CD31 and CD34 and macrophage
marker CD11b (Figures 2A). Murine MSC were characterized based on the positive
expression of Sca-1, CD106, CD44 and CD140b and the negative expression of
CD45, CD31, cKit and CD11b (Figures 2B).
To confirm their multipotent potential, human and murine MSC were subject to
differentiation assays. Naïve human MSC, or adenoviral transduced Ad-MSC both
show trilineage differentiation potential. Furthermore, lentiviral transduced shRNA
CD44 MSC and shNeg transduced MSC were also subject to trilineage
differentiation. shCD44 MSC displayed diminished capacity for adipocytes
differentiation (Figure 3). Murine MSC showed comparable differentiation into bone,
cartilage or fat. The murine CD44 KO MSC displayed bone and cartilage potential
but hindered adipocyte differentiation potential. Additionally, adenoviral infected
MSC do not lose their differentiation potential (Figure 4). Osteoblasts were identified
by alkaline phosphatase and Alizarin Red S staining. Adipocytes were identified by
Oil Red O stained lipid vacuoles. Chondrocytes were identified by Alcian Blue
stained mucopolysaccharides.

35

Figure 2. MSC characterization by flow cytometry. Phenotypic surface marker
expression was evaluated on (A) human MSC and (B) murine MSC.
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Figure 2

37

Figure 3. Human MSC trilineage differentiation potential. MSC cultured in
adipocyte, chondrocyte or osteoblast differentiation medium. (A) Oil Red O stain
verified the presence of mature adipocytes. (B) Alkaline phosphatase substrate and
(C) Alizarin Red S stained for mature, calcium-producing osteocytes, and (D) Alcian
Blue stained for mature chondrocytes.
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Figure 3.
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Figure 4. Murine MSC trilineage differentiation potential. Naïve and viral
transduced MSC cultured in adipocyte, chondrocyte or osteoblast differentiation
medium. (A) Oil Red O stain verified the presence of mature adipocytes. (B)
Alkaline phosphatase substrate and (C) Alizarin Red S stained for mature, calciumproducing osteocytes, and (D) Alcian Blue stained for mature chondrocytes.
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Figure 4.
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3.2 Defining characteristics of tumor tropic MSC
3.2.1 Chemokine and cytokine expression profiles
RNA was extracted from MSC stimulated with tumor conditioned media for 24
hours. cDNA was synthesized and run on a SABiosciences chemokine/cytokine
array. Both human and murine MSC were stimulated with breast (MDA-231, 4T1),
ovarian (Skov-3, ID8), prostate (PC-3) and pancreatic (Panc-1) tumor cell lines to
analyze the MSC autocrine response to tumor stimulation. Resulting chemokine
expression up regulated by tumor conditioning varied between tumor models,
although there were a few overlapping expression profiles including IL8, IL1,
CXCL1, CXCL5 and C3. Then, tumor cell lines were analyzed for chemokine and
cytokine expression in order to compare autocrine and paracrine chemokine
expression. One factor that was unique to tumor paracrine stimulation in the Skov-3
ovarian cell line compared to chemokines expressed by other tumor cell lines was
osteopontin (OPN; Figure 6A). This ligand was further pursued because our
previously published data showed Skov-3 tumor cells are highly attractive to MSC
compared to other adenocarcinoma cell lines both in vitro and in vivo (60). By
ELISA, we show the Skov-3 tumor cell line secretes OPN (40ng/ml+/-3) as
compared to no secretion by Panc-1 or MDA-468 tumor cells and limited secretion
by MSC (1ng/ml) and HUVEC (2ng/ml). 12 additional breast and pancreatic tumor
cell lines were negative for OPN secretion. (data not shown) Furthermore, tumor
cell lines and MSC conditioned by tumor cell lines were analyzed for gene
expression of OPN by PCR. MSC express OPN which is increased following tumor
conditioning by both high (Skov-3) and low (MDA-468 and MCF7) expressing cell
lines (Figure 6C). Then tissue sections from tumor-burdened mice were analyzed
for OPN expression by immunofluorescence. Three xenograft and two syngenic
tumor models showed varied OPN staining; all tumor sections had patches of
strongly positive OPN staining (Figure 6D). Furthermore, the majority of the normal
tissue of a tumor-burdened mouse stained was negative for OPN with exception of
the liver. OPN positive stain per slide section was quantified and averaged across
each tissue section (Figure 6E).
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Figure 5. Chemokine and cytokine expression by tumor stimulated MSC. Realtime PCR was conducted on human and murine MSC lysates extracted after 24
hour stimulation with (A) MDA-231, (B) 4T1, (C) Skov-3, (D) ID8, (E) Panc-1 or (F)
PC-3 tumor cell conditioned media.
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Figure 5
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Figure 6. Expression of CD44 ligand in tumor cell lines and tissues. (A)
Osteopontin (OPN) was among the chemokines expressed by Skov-3 tumor cells
by RT-PCR chemokine array (SA Biosciences). (B) OPN secretion by breast (MDA468), ovarian (Skov-3) and pancreatic (Panc-1) tumor cells was confirmed by ELISA
and compared against normal cell lines including endothelial cells (HUVEC) and
MSC. (C) OPN gene expression was analyzed in tumor cell lines, MSC, and tumor
conditioned MSC (D) OPN positive tissue sections were confirmed by IF and (E)
quantified using InForm software (CRi, Woburn, MA).
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Figure 6
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3.2.2 In vitro migration of MSC
Tumor-secreted paracrine factors are chemoattractive to MSC. A scratch assay
showed the visible difference in MSC motility subjected to Skov-3 conditioned
media versus serum or serum free media. The difference was empirically measured
by defining the edge of the scratch at time zero and calculating the distance of
enclosure at 6, 12 and 24 hours. The Skov-3 conditioned MSC were able to
permeate the demarcated scratch border faster than the serum or serum free
conditioned MSC (Figure 7A). Then, we compared conditioned media from two
highly invasive and aggressive tumor cell lines: Skov-3 and MDA-231. Tumor
conditioned media (TCM) is as attractive as full, 20% serum media. 10-fold dilutions
in conditioned media correlate with less MSC migration (Figure 7B). Furthermore,
the Skov-3 cells were more attractive than the MDA-231, which may be explained
by the dramatic difference in OPN secretion by the Skov-3 cells (Figure 6B).
Next, blocking antibodies for a number of chemokine receptors corresponding to the
chemokines expressed by the tumor cells were used to inhibit MSC transwell
migration toward Skov-3 conditioned media (SCM). Among the neutralizing
antibodies tested, blocking CD44 severely inhibited MSC migration (Figure 7C).
Cell surface expression of CD44 was confirmed before and after SCM stimulation.
Interestingly, by flow cytometry, the cell surface expression of CD44 was
consistently decreased compared to the serum free control (Figure 8A). However,
by both western blot and by immunocytochemical staining for CD44, there was no
decrease in total CD44 level (Figure 8B and C). To resolve this discrepancy, we
transfected MSC with a CD44 luciferase promoter construct and then subjected
them to TCM. We chose breast cancer cell lines (conditioned media generously
given to us by Dr. M.C. Hung) with variable levels of invasiveness as well as the
Skov-3 and Panc-1 cell lines.
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Figure 7. Migration of hMSC to tumor conditioned media. (A) MSC under Skov3 conditioned media (SCM) permeate (leading edge identified by red line) the
demarcated (black dotted line) “scratch” earlier than the serum or serum free (SF)
stimulated MSC indicating enhanced motility. (B) MSC migration toward Skov-3 and
MDA-231 conditioned media in 10-fold dilutions. (C) Neutralizing antibody inhibition
of

MSC

toward

Skov-3

conditioned

media

corresponding to the tumor secreted chemokines.
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Figure 8. CD44 expression on human MSC. CD44 expression was evaluated
after 24 hours of Skov-3 conditioning and compared to naïve MSC. (A) Flow
cytometric analysis of CD44 before (red) and after Skov-3 conditioning (blue). (B)
Western blot of CD44 expression in MSC. (C) IF staining of MSC with CD44 (Alexa594). (D) CD44 promoter activity in MSC following tumor conditioning measured by
relative luciferase activity.
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Figure 8.
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3.2.3 Blocking CD44 inhibits tumor-tropic MSC migration
MSC expressed CD44 was blocked using several different methods. First, CD44
neutralizing antibody was used to block migration towards SCM by 80%+/-4%
(Figure 9A). Then, MSC transiently transfected with siRNA against CD44 showed
60%+/-11% reduction in migration towards SCM as compared to the naïve control
(Figure 9B and 9C). Furthermore, stable knockdown of CD44 in MSC was achieved
using a combination of four shRNA hairpins (Open Biosystems, Huntsville, AL). The
stable knockdown shows similar migration inhibition to the transient knockdown of
CD44, 68%+/-5% (Figure 9D and 9E).

Alternatively, using a small Hyaluronan

oligomer (oHA) that competitively inhibits CD44 also inhibits migration by 60%+/-4%
(Figure 9F). Finally, we used an adenoviral expressed soluble CD44 (s44) as an
inhibitor of CD44. We tested the adenovirus secretion of s44 by expressing it either
from the Skov-3 tumor cells producing the conditioned media (Figure 9G) or the
migrating MSC (Figure 9H). Whether the s44 was expressed in the SCM or the
MSC, there was a significant inhibition in migration at an MOI of 5000. This was the
MOI chosen for subsequent in vivo experiments.
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Figure 9. Migration inhibition of MSC toward Skov-3 conditioned medium.
MSC migration was blocked using (A) neutralizing antibody and (B) siRNA against
CD44. (C) Western blot shows degree of transient knockdown in MSC; (D) Stable
knockdown of CD44 shows migration inhibition similar to transient knockdown; (E)
Western blot shows the degree of stable knockdown in MSC (F) HA oligomer
inhibits MSC migration at 100µg/mL. (G) Conditioned media from s44 expressing
Skov-3 tumor cells or (H) s44 transfected MSC also inhibit MSC migration toward
Skov conditioned media.
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Figure 9.
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3.2.4 Inhibition of tumor tropic MSC migration in vivo
5x105 Skov-3 cells were subcutaneously (SC) injectioned bilateral to the inguinal fat
pads of SCID mice. Following tumor engraftment, 54 days after injection, mice were
separated into four groups of mice (n=5). 2 groups of mice (blue and red in Figure
10) were given intratumoral injections of 2.5x1011 vp of Ad-s44 in the right leg. Tail
vein injections of 1x106 MSC were given 48 hours later. Two groups of mice (black
and blue in Figure 10) received control MSC and the other two groups, green and
red, received Ad-s44 expressing MSC. Mice were imaged consecutively for 5 days
post MSC injection and were then sacrificed on day 6. Day 2 had the greatest influx
of MSC as quantified with BLI, and displays a statistically significant (p<0.01)
decrease in MSC migration into the tumors that expressed sCD44 (blue and red)
and into the tumors belonging to the mice that received the Ad-s44 MSC (green and
red). The mice receiving both the intratumoral Ad-s44 injection and the Ad-s44MSC (red) were not significantly different from those mice that received one or the
other (Figure 10B). The control mice (black) with normal Skov-3 tumors and normal
MSC showed a normal and equal localization of MSC to the bilateral tumor sites,
whereas the of mice receiving MSC infected with Ad-s44 did not. Figure 10C shows
the region of interest surrounding each tumor-burden corresponding with the left
and right tumors in each of the four groups. Immunohistochemical staining of the
right tumors shows the infiltration of MSC by CD105 staining. Those mice that
received both intratumoral Ad-s44 injections and Ad-s44-expressing MSC had less
MSC compared to the control tumor evident by immunohistochemical staining for
CD44 and CD105 (Figure 10D).
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Figure 10. In vivo tumor-tropic migration of MSC is inhibited by s44. MSC were
injected systemically into bilateral xenograft Skov-3 tumor burdened NOD/SCID
mice in the presence or absence of the Ad-s44. (A) Time line of the mouse
experiment. (B) BLI average of the right ROI in each group shows that any mouse
receiving s44 had a decrease in tumor tropic MSC migration. (C) Representative
ROI of each tumor. Yellow arrows indicate the tumors that received intratumoral
injections of Ad-s44. (D) Immunohistochemical staining of tumor sections shows the
presence of MSC by CD105 staining, and the presence of s44.
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Figure 10.
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3.2.5 CD44 signaling in MSC migration
To begin to understand the mechanism of MSC migration through CD44, we used
the oHA oligomer on MSC with 6 or 24 hours of SKM and analyzed CD44
expression by confocal microscopy. Using InForm software to quantify the mean
CD44 fluorescent pixels within the nucleus versus the cytoplasm we were able to
determine that oHA blocks the nuclear localization of CD44 under tumor
conditioning (Figure 11A). Because matrix metalloproteinases are an integral part
of invasion and migration, we looked at MMP2 and 9 levels in MSC with and without
tumor conditioning. We saw an increase in MMP2 and MMP9 activation in MSC
under tumor conditioning (Figure 12A). Using an MMP inhibitor against MMP14
(and MMP2 and MMP9 at lower concentrations), we saw a decrease in migration
comparable to that achieved with s44 (Figure 12B). To elucidate whether CD44induced migration could be dependent on MMP, we analyzed CD44 expression by
western blot, using the MMP inhibitor and tumor conditioning. At a concentration of
1µM, MMP inhibition leads to visible changes in MSC CD44 cleavage products
(Figure 12C). The extracellular membrane portion can be found ~34kDa and the
intracellular membrane portion can be found at ~17kDa. Figure 12D illustrates the
structure of CD44. When we use an MMP inhibitor we see ablation of the CD44
cleavage products, suggesting that MMP14, MMP9 or MMP2 are involved in CD44
cleavage in response to tumor conditioning.

59

Figure 11.

MSC expressed CD44 localized to the nucleus following

stimulation with SCM. (A) Mean pixel density of Alexa594-labeled CD44 colocalizing with nuclear-DAPI in MSC following 6 or 24 hours of Skov-3 conditioning.
Tumor induced nuclear localization of CD44 is blocked by oHA in MSC. (B)
Representative images of oHA treated Skov-3 conditioned MSC.
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Figure 11
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Figure 12. MMP activation in tumor conditioned MSC drives migration partially
through CD44. (A) MMP expression is up regulated in tumor conditioned MSC. (B)
Using an MMP inhibitor to block MMP2 at 20nM, MMP9 at 200nM and MMP14 at
1µM. MSC migration was inhibited to a level consistent with that of s44 inhibited
migration. (C) Western blot shows that MMP inhibition at 1µM is able to inhibit the
CD44 cleavage products including 34kDa extracellular portion and the 17kDa
intracellular portion. (D) Illustration of CD44 receptor including the extracellular and
the intracellular cleavage sites, the region containing the CD44 variants and the
only known ligand binding domain.
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Figure 12
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3.2.6 CD44 activation by TCM induces twist expression
To elucidate potential downstream targets of the nuclear CD44, we analyzed
potential transcriptional targets involved in both mesenchymal cell phenotype and
migrational phenotype. Expression of the transcription factor Twist down regulated
in the presence of s44 even when stimulated by SCM (Figure 13A). We then
decided to look at Twist expression following MMP inhibition as shown in Figure
12C—the MMP inhibition that blocked CD44 cleavage products. Twist expression
was slightly decreased in the MSC in lane 4 (Figure 13B).
Knocking down expression of CD44 in human MSC using four shRNAmir hairpins in
pGIPZ vectors (OpenBiosystems, Huntsville, AL); we were able to suppress CD44
expression in MSC by greater than 95%. Furthermore, the protein expression of
Twist in the shCD44 MSC is decreased in the tumor conditioned MSC at both
30minutes and 24 hours (Figure 13C). The twist expression levels were also
confirmed by real time RT PCR. Twist expression is down regulated in tumor
conditioned shNeg MSC that were treated with s44 or with 1µM MMPI. This down
regulation is similar to that observed from the shCD44 MSC with or without tumor
conditioning (Figure 13D).
The shCD44 MSC were previously subjected to a transwell migration assay that
confirmed deficient migration towards tumor conditioned media. Next, we
transfected shNeg MSC or shCD44 MSC to exogenously express HA-tagged Twist.
There was a 130 fold increase in Twist expression by RT PCR (Figure 13E) and HA
the presence of HA is evident by western (Figure 13F). These Twist expressing
shCD44 MSC were subjected to a transwell migration assay toward tumor
conditioned media. The exogenous expression of Twist showed a 12% increase in
migration of the shCD44MSC compared to no Twist. The shNeg MSC transfected
withTwist showed a significant decrease in migration as compared to the control
cells. There was no migratory inhibition of shCD44MSC with or without Twist in the
presence of 100µg/mL oHA (Figure 13G).
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Next, ChIP was performed to assess the transcriptional regulation of Twist by
CD44. Primers to the distal and proximal promoter regions of Twist were used to
confirm CD44 complex with Twist promoter. The proximal promoter region was
pulled down with CD44 following 24 hours of tumor conditioning (Figure 14A). The
assay was performed at an earlier time point to confirm CD44 binding to the Twist
proximal promoter following 30 minutes of tumor conditioning (Figure 14B).
Furthermore, we also assessed the binding of CD44 to the Twist promoter under
the stimulation of soluble CD44 and tumor conditioning. Under these conditions,
there is a decrease in association between CD44 and the Twist promoter (Figure
14C).
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Figure 13. Inhibition of CD44 on MSC leads to decreased Twist expression. (A)
MSC gene expression of Twist by MSC is decreased in the presence of s44 and
tumor conditioned media as compared to tumor conditioned media alone. (B) MMP
inhibition of tumor conditioned MSC leads to decrease in Twist protein expression
after 24 hours. (C) CD44 shRNA knockdown of human MSC shows decrease in
Twist expression following 30minutes and 24 hours of tumor conditioning. (D) Gene
expression of Twist by RT PCR is lower in shCD44 transduced MSC (red)
compared to shNeg transduced MSC (blue) and is comparable to the shNeg MSC
treated with s44 or with 1µM MMPI. (E) Exogenous expression of Twist in shNeg
MSC (green) or shCD44 MSC (yellow) was increased by >130 fold compared to
non-transfected MSC. (F) HA-tagged Twist-transfected MSC shown by western blot.
(G) Transwell migration assay of Twist transfected shCD44MSC shows a 12% gain
of migration towards tumor conditioned media compared to the shCD44MSC
without Twist.
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Figure 14. Tumor conditioned MSC induce CD44 binding to Twist promoter by
ChIP. (A) Initial ChIP assay was done after 24 hours of tumor conditioning. Only
Twist Proximal promoter primers showed expression fold changes by RT-PCR. (B)
Using only the Twist proximal primers, Twist promoter could be associated with
CD44 pulldown at 30 minutes following stimulation. (C) Additionally, a large
decrease in binding is seen between naïve MSC and MSC stimulated with TCM and
soluble CD44.
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3.3 Incorporation of MSC within the tumor microenvironment
3.3.1 Tumor conditioned MSC differentiate into activated fibroblasts
An activated fibroblast is a fibroblast conditioned by a pathogenic incident. Within
the tumor microenvironment, these fibroblasts are known as tumor (carcinoma)
associated fibroblasts (TAF or CAF). The heterogeneous population of TAF can be
currently defined by a group of markers that characterize aggressiveness by ECMaltering protein expression, vascularization potential by pro-angiogenic proteins
expressed and secreted and growth potential by the growth factors secreted (Figure
15A).

MSC that are conditioned over a period of 21-31 days in vitro are

differentiated into TAF as defined by expression of Tn-C, TSP1 and FSP, and an
increase in expression of FAP, αSMA, and desmin (Figure 15B).
Similarly, IV injected MSC that home to tumors, or MSC admixed with tumor cells
prior to tumor engraftment show a marked increase in TAF-associated expression.
Following three months in vivo, Skov-3 xenograft tumors that had been admixed
with MSC were removed and analyzed for the expression of activated fibroblast
expression of FAP and FSP (Figure 16A and B), aggressive/invasive markers Tn-C,
TSP and SL1 (MMP3) (Figure 16C-E), neovascularization markers αSMA, desmin
and VEGF (Figure 16 F-H) and finally growth factor expression of HGF, EGF and
IL6 (Figure 16 I-K).
Furthermore, MSC incorporation as tumor stroma is not exclusive to one tumor
type. While we focus primarily on Skov-3 ovarian carcinoma, we briefly show the
potential for the MSC to incorporate into both breast (MDA-231) and pancreatic
(Panc-1) tumors (Figure 16L-P).
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Figure 15. MSC can differentiate into TAF. (A) The expression of several markers
defines the heterogeneous population of the TAF. (B) After 21 days in tumor
conditioned medium, MSC differentiate into TAF, as defined by the appearance of
FSP, TSP1 and Tn-C, and the increase in αSMA, FAP and desmin.
* Figure published in PlosOne 2009, Spaeth et al.
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Figure 16. Expression of TAF markers in MSC-admixed Skov-3 tumors in vivo.
Following three months of tumor engraftment, excised tumors were analyzed by
IHC for the presence of TAF markers. Activated fibroblast proteins (A) FSP, (B)
FAP were scattered in a non-uniformed branching network. The ECM-modifying
proteins (C) Tn-c and (D) TSP1 are found throughout the tumor whereas (E) SL1 is
found localized to the leading edge of the tumor. The myofibroblast markers
including (F) αSMA and (G) desmin are found throughout the tumor and are
associated with neovascularization as endothelial-supportive cells and the growth
factor (H) VEGF is more highly expressed in localized regions of the admixed
tumor. Additional growth factors expressed within the tumor microenvironment at
higher levels than in the tumor alone include (I) HGF, (J) EGF and (K) IL6. (L)
Expression of MSC marker, Thy1 shows co-localization in adjacent tumor sections
with (M) α-SMA + stained Skov-3, MDA-231 and Panc-1 xenograft tumors.
Additional TAF markers shown include: (N) desmin (O) TSP1 and (P) Tn-C.
* Figure published in PlosOne 2009, Spaeth et al.
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Spaeth et al.2009. PLoS ONE 4(4): e4992

76

3.3.2 MSC as TAF contribute to tumor growth
In vivo, we showed the presence of growth factors by IHC (Figure 16). In vitro, MSC
express and secrete multiple growth factors, chemokines and cytokines when
stimulated by tumor conditioned media. Measuring IL-6, TGFβ, VEGF and HGF
expression by ELISA from both the MSC stimulated by the SKM (Figure 17A) or
from the Skov-3 tumor cells stimulated by the MSC conditioned medium (Figure
17B) we see an increase in growth factors within the medium in all cases with the
exception of HGF which is not induced in MSC by SKM. VEGF is not significantly up
regulated and the increased presence of HGF is due to HGF secreted by the MSC.
The MSC within the tumor microenvironment give rise to TAF which are supportive
and capable of enhancing tumor growth in vivo. Comparing Skov-3 only tumors to
Skov-3/MSC admixed tumors, there is a significant although delayed growth
advantage (Figure 17C). Furthermore, we attribute this growth advantage to the
human MSC and not the mouse stromal MSC participation. In an in vitro tumor
growth assay, Skov-3 cells were admixed with a BALB/c, c57 murine MSC cell lines
or with fibroblasts and compared against the human MSC. The human MSC
provided a significant growth advantage to the Skov-3 tumor cells over a period of
eight days (Figure 17D).
An in vitro tumor growth assay was used to assess the MSC secreted growth factor
that was driving Skov-3 tumor cell proliferation. First, Skov-3 tumor cell proliferation
was analyzed alone, with MSC conditioned media or with the exogenous addition of
FGF, HGF, TGF-β, VEGF, EGF or IL-6. EGF and IL-6 showed the most potentate
proliferative advantage next to MSC conditioned media (Figure 17E). Next, to
determine whether the MSC conditioned media was the source of the IL-6 and EGF
that was promoting cell proliferation, the same assay was set up with MSC
conditioned media that had had EGF or IL-6 immunoprecipitated out of solution. By
immunoprecipitating IL-6, but not EGF out of the MSC conditioned media, the
proliferative advantage of the Skov-3 cells was significantly hindered (Figure 17F).
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Figure 17. Growth advantage of tumors admixed with MSC. Growth factors
potentially attributing the growth advantage of Skov-3 tumors admixed with MSC
were measured by ELISA. (A) IL-6, TGFβ and VEGF are all increased in MSC
supernatant following SCM. Likewise, (B) IL-6, TGFβ, VEGF and HGF were
increased in Skov-3 supernatant following MSC conditioning. (C) In vivo tumor
growth advantage of admixed tumors was delayed yet apparent after day 80. (D)
Neither murine MSC nor fibroblasts have the same growth advantage as human
MSC do on Skov-3 tumor cell proliferation in an in vitro tumor growth assay. (E)
Skov-3 proliferation was analyzed in a tumor growth assay using MSC conditioned
media or growth factors alone. (F) immunoprecipitation (IP) of EGF or IL-6 from
MSC conditioned media showed that Skov-3 cell proliferation is inhibited with the
removal of MSC secreted IL-6.
* Figure published in PlosOne 2009, Spaeth et al.
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3.4 CD44 deficient MSC become inadequate TAF
3.4.1 sh44 MSC are deficient as a supportive stromal cell
The MSC, as a stromal cell is able to support cell growth and maintenance through
the production of growth factors, chemokines and cytokines. Through paracrine
stimulation, MSC are proangiogenic; they are able to induce in vitro endothelial tube
formation. The stable shCD44 MSC cell line showed a decreased propensity to
support endothelial (HUVEC) tube formation and stabilization in vitro. Naïve MSC
can initiate and maintain endothelial tube formation including a large quantity of
nodal structures after conditioning whereas shCD44 MSC conditioned HUVEC are
not able to form as many nodal structures intersecting single tubes. These can be
enumerated by manual counting of the tubes per field of view under the light
microscope. Furthermore, the naïve MSC are able to sustain support beyond 10
days where as the shCD44MSC media does not support or sustain tube formation
in HUVEC past 8 days. By quantifying tube formation at day 7, the shCD44 MSC
show a decreased capacity (p<0.001) to induce and maintain HUVEC tube
formation of 53% compared to naïve MSC (Figure 18A). To elucidate what
proangiogenic growth factors could be affected by knockdown of CD44 in MSC, we
evaluated the gene expression of growth factors including VEGF A, VEGF C, EGF,
TGFα, IL-8 and OPN. The gene expression of VEGF C, EGF, TGFα and IL-8 is
decreased in the shCD44MSC compared to shNeg MSC. Furthermore, when Twist
was exogenously expressed in the shCD44MSC, the expression of all six growth
factors increased in expression (Figure 18B).
Finally, we looked at the expression of TAF markers following long term (21 day)
tumor conditioned sh44MSC compared to shNeg MSC. The expression of FAP,
FSP and TSP1 are significantly decreased in the shCD44MSC population. The
expression of α-SMA and PDGFR-β is decreased. And, while the levels of total
vimentin are not different between the shCD44MSC and the shNeg MSC, the
protease cleavage fragments of vimentin are less in the shCD44MSC. The
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expression level of Twist is also decreased in the shCD44MSC following long term
tumor conditioning (Figure 18C).
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Figure 18. Deficient stromal supportive features of shCD44MSC. (A) In vitro,
MSC (or shNeg MSC control) conditioned media induced tube formation on HUVEC
up to 12 days in culture. HUVEC conditioned by shCD44MSC formed 53% fewer
tubes compared to naïve MSC (p<0.001). Tubes were manually counted under a
light microscope (4 fields of view per well x3 wells). (B) Growth factor gene
expression fold change of shCD44MSC (red) or shCD44MSC+Twist (blue) following
24 hour tumor conditioning. Fold change relative to tumor conditioned shNeg MSC.
(C) TAF marker expression in long term (21 day) conditioned shCD44MSC
compared to shNeg MSC showed decreased expression of nearly every TAF
marker evaluated.
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3.4.2 Characterization of CD44 deficient murine MSC
To further investigate the role of CD44 in MSC, CD44 knockout mice were
purchased from Jackson Labs (Bar Harbor, Maine). MSC isolated from these mice
express Sca-1, but not CD140b, CD106 or CD44 (Figure 19A). When compared to
their wild type counterparts, the CD44KO MSC have impaired migratory capacity
towards ID8 tumor conditioned media in vitro (Figure 19B). Next, we saw a
decrease in basal levels of Twist expression in CD44KO MSC versus WT MSC in
addition to a change in PDGFR-β bands (Figure 19C). Both of these changes were
seen in the human sh44MSC. The most striking difference between the two MSC
was the lack of detectable FAP expression in the CD44KO mice at basal levels, with
tumor stimulation or with TGF-β stimulation (Figure 19D).
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Figure 19. Characterization of murine CD44KO MSC. (A) Phenotypic surface
marker expression of CD44KO MSC. (B) Overall migration capacity of CD44KO
MSC compared to wild type C57/b6 MSC. (C) Comparison of marker expression of
activated fibroblast markers under TCM (ID8) shows no CD44 expression and
altered PDGFRβ expression and the levels of (D) FAP expression could not be
induced.
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3.4.3 Delayed tumor progression in CD44KO mice
To elucidate whether CD44KO mice are have less tumor promoting potential
compared to WT mice, 2x105 EO771 tumor cells were engrafted SC into the
CD44KO (n=10) or WT (n=10) mice. Tumor growth was followed by daily caliper
measurements. The majority of tumors were palpable by day 8. On day 17 there
was a significant difference (p<0.05) between the size of the tumor in the WT mice
compared to the CD44KO mice (Figure 20A). The first mice died in the control
group on day 18. All of the mice were sacrificed due to tumor burden 30 days
following tumor engraftment. At this time there were 6 mice remaining in the
CD44KO group and only 1 remaining in the WT group. There was a significant
difference in survival between tumor burdened WT mice and tumor burdened
CD44KO mice by Log-rank test (p<0.05; Figure 20B).

One marked difference

between the two groups was the size of the spleen in the CD44KO mice was
consistently 2x larger than in the WT mice. Otherwise, all of the organs were similar
in appearance. There were no signs of lung or lymph node metastases.
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Figure 20. Tumor growth in CD44KO mice compared to WT mice. (A) Caliper
measurements from the mice (n=20) were analyzed 17 days following tumor
engraftment. Tumor size in CD44KO mice is significantly smaller (p<0.05)
compared to WT mice. (B) Kaplan-Meier curve of WT versus CD44KO mice
following EO771 tumor engraftment shows significant difference (p<0.05). All mice
were sacrificed on day 30.
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3.4.4 Tumor microenvironment impact of CD44KO MSC
Next, we asked whether the inability of the CD44 deficient MSC to support
angiogenesis in vitro was associated with the vascularization potential of the MSC
(or the tumor conditioned MSC, the TAF) in vivo. Briefly, murine CD44KO MSC or
murine WT MSC were admixed with 4T1 tumor cells at a 1:1 ratio, a total of 2x105
cells, and engrafted into the mammary fat pad of SCID mice. Following 3 weeks of
tumor engraftment, the mice were sacrificed and the tumors excised, paraffin
embedded and processed for immunofluorescent staining. Compared to tumors with
admixed wild type MSC, the tumors admixed with CD44KO MSC contained fewer
stromal components that are normally provided by MSC-differentiated tumor
associated fibroblasts. α-SMA expression, indicative of myofibroblast and pericyte
presence and vessel stability in neoangiogenesis, is increased in MSC admixed
tumors compared to tumor alone. In CD44KO admixed tumors, the expression level
of α-SMA is reduced to the level seen in tumors without admixed MSC (p<0.001;
Figures 21A and B). Likewise, vessel presence was measured by the endothelial
cell marker, CD31. Its expression is also decreased in the CD44KO MSC admixed
tumors compared with the wild type MSC admixed tumors (p<0.05; Figures 21C
and D). Finally, the expression levels of FAP and FSP, proteins indicative of
“activated” fibroblasts or tumor associated fibroblasts, are similarly decreased in the
CD44KO MSC admixed tumors when compared to the wild type MSC tumors
(p<0.001 for both; Figures 21E-F).
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Figure 21. CD44KO MSC/4T1 admixed tumors have less tumor associated
fibroblast presence and less vascularization in vivo. Paraffin embedded 4T1
tumors alone or admixed with either CD44KO MSC or WT MSC were analyzed for
the presence of myofibroblast marker (A) α-SMA, a marker of vascular support. (B)
Quantitative analysis of α-SMA staining across all slides. (C) The presence of
endothelial cells was confirmed by CD31 positive staining and (D) quantified. (E-F)
FAP positive staining represents activated fibroblasts in the tumor stroma as does
(G-H) FSP positive staining. In IF images, stained cells are shown in white but are
shown in red in the mock-brightfield images.
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3.4.5 CD44-deficient stroma tumor growth deficiency
SCID mice were given contralateral tumor injections in the inguinal fat pads. The
mice in Group 1 received a 1:1 admixture of CD44KO MSC and 4T1 (2x105 total) on
the right and 2x105 4T1 cells alone on the left. Mice in group 2 received the same
number of cells but a 1:1 admixture of WT MSC and 4T1 on the right and 4T1 alone
on the left. Three weeks after engraftment, mice were sacrificed and tumors were
weighed in order to compare discrepancies in tumor size. Group 1 resulted in 4T1
tumors significantly larger than the admixed 44KO MSC/4T1 tumors (p<0.05; Figure
22A). In group 2, the WT MSC/4T1 tumors were larger than the 4T1 tumors (p=NS;
Figure 22B).
Representative image of excised tumors shows the CD44KO Admixed tumors from
group 1 were significantly smaller than the opposite tumor but not smaller than the
tumors from the mice in group 2 (Figure 22C). One potential reason for the tumor
size discrepancy between groups may have to do with the macrophage presence in
the mice. Represented by F4/80 positive staining, 4T1 tumors and WT MSC/4T1
tumors did not have statistically significant differences in the macrophage marker
whereas CD44KO MSC/4T1 tumors had 40% less infiltration (Figure 22D).
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Figure 22. Differences in tumor size between CD44KO MSC/4T1 admixed and
control tumors. Three weeks prior to tumor excision, mice received an injection of
either CD44KO MSC/4T1 or WT MSC/4T1 bilateral to 4T1 alone. Tumor weight (g)
was measured in both sets of mice. (A) Group 1 mice received CD44KO MSC/4T1
tumor bilateral to 4T1 were significantly smaller in tumor size (p<0.05). (B) Group 2
mice received WT MSC/4T1 tumor bilateral to 4T1 and did not show a significant
difference between tumor sizes (C) Representative images of excised tumors from
mouse in group 1 versus mouse in group 2. (D) The macrophage infiltration was
depicted by F4/80 staining. Macrophage infiltration is less in the CD44KO MSC/4T1
(p<0.01) group and not altered between WT MSC/4T1 tumors and 4T1 alone.
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3.4.6 Tumor recruitment of CD44KO bone marrow derived stroma
After evaluating the tumor stroma participation of the CD44KO MSC as TAF in the
non-physiological 1:1 admixing experiment, we asked whether the TAF deficiencies
would be similar in a physiologically relevant situation. Thus, bone marrow
transplants were conducted using ubiquitous-expressing GFP recipient mice to
evaluate the contribution of CD44KO bone marrow stromal populations to the tumor
microenvironment. The GFP recipients were lethally irradiated (9Gy) and
transplanted with whole bone marrow from LacZ labeled CD44KO mice or from
mice expressing tdTomato (Red) under the gtROSA promoter (Figure 23A).
Schematic diagram of the bone marrow transplant is shown in Figure 23B. Four
weeks following engraftment, the bone marrow transplants were confirmed by Flow
cytometry (Figure 23C). Then, 2x105 EO771 tumors were injected SC and allowed
to engraft. Mice were sacrificed 35 days following tumor engraftment; tumors, lungs,
liver, spleen and bone marrow were collected for analysis by immunostaining. There
were very few differences between the transplant groups as seen by H&E staining
(Figure 24A). The marked difference was observed between the tumors within the
groups. The tumors engrafted in the CD44KO BMT mice displayed less stromal cell
dispersion compared to those in the Red BMT mice. Furthermore, the calculated
percentage of stromal cell engraftment in the two representative tumor images is
6.9% in the CD44KO BMT derived tumor compared to 20.1% in the Red BMT
derived tumor. Percentage of stromal cell within the images was calculated based
on the Eosin-positive staining using Nuance software (Figure 24C).

98

Figure 23. Bone marrow transplantation into GFP recipient mice. Whole bone
marrow was collected from ubiquitously expressing tdTomato mice (red) or
CD44KO mice (blue) and transplanted into lethally irradiated ubiquitously
expressing GFP mice (green). (A) The color and CD44 status of the bone marrow
was confirmed by flow cytometry prior to transplantation. (B) Schematic diagram of
transplantation shows GFP recipient mice receiving either Red BMT (group1) or
CD44KO BMT (group2). (C) Four weeks following engraftment, blood was drawn
from each transplant recipient (Red BMT, n=5; CD44KO BMT, n=5) to confirm the
status of the BMT.
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Figure 24. H&E stained organs and tumor sections of BMT mice. There is no
visible difference between the organs of the Red BMT versus CD44KO BMT
recipient mice as seen by (A) H&E staining of tumors and organs. Images are from
two individual mice from each group. (B) However the H&E stained tumor from the
CD44KO BMT mice exhibit less stroma incorporation compared to the Red BMT
engrafted tumor. H&E staining colors were enhanced by InForm; light blueÆdarker
blue and pinkÆred.
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3.4.7 CD44KO stromal participation in the tumor microenvironment
Next, we needed to deduce the origin of the tumor stromal participants, whether
bone marrow derived or host derived. The tumors from the tdTomato (Red) BMT
were analyzed for the co-expression of RFP (to label the BMT cells) or GFP (to
label the host cells) and the TAF markers FAP, FSP and α-SMA, and the
endothelial marker CD31. Likewise, the CD44KO BMT were analyzed for the coexpression of LacZ (to label the BMT cells) or GFP (to label the host cells) and FAP,
FSP, α-SMA and CD31. Co-expression was characterized using InForm software
to identify immunostaining co-localization. Briefly, each cell was identified based on
the expression of the nuclear stain DAPI (average of 2000 cells per image). Then,
the fluorescent intensity of each fluorescent label per cell was enumerated. The
fluorescent intensities were plotted (488 label on the Y axis and 594 on the X axis)
and co-stained cells were quantified. Figure 25 illustrates the process of spectral
unmixing, cell segmentation based on nuclear stain and the quantitation of an
image stained with α-SMA+ and GFP+. Corresponding fluorescence intensity plot of
co-stained cells correlates to the image (Figure 25I).
In tumors from both CD44KO BMT mice and Red BMT mice, the GFP host cells
were found to co-express with the FAP (Figure 26A), FSP (Figure 26B), α-SMA
(Figure 26C) and CD31 (Figure 26D) markers more than the respective β-gal+ or
RFP+ bone marrow derived cells.
Briefly, the number of cells assessed (n) for the co-expression of each maker pair
was 100,000 on average. The following percentages were calculated based on the
co-stained cells in the numerator and the total number of cells (n) in the
denominator. Red bone marrow derived stromal presence (RFP+) in the tumor was
limited. The overall prevalence of the GFP+ cells expressing FAP, FSP, α-SMA or
CD31 (6.1%+/-2.3%) from the Red BMT mouse derived tumors was greater than
the RFP+ cells expressing any of the four markers (0.7%+/-0.3%; Figure 27A).
There was a significant difference between the GFP+/CD31+ cells and the
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RFP+/CD31+ cells within the tumor (p<0.001) but no significant difference between
any of the other markers. Again, percentages displayed in Figures 27A-C of GFP+
or RFP+ or β-gal co-stained cells in tumors from BMT mice were calculated
averages of co-stained (double positive as explained in Figure 25I) cells per total
number of cells per tumor image was calculated between 5 mice and 10 images per
tumor.
CD44KO bone marrow derived stromal presence (β-gal+) in the tumor was overall
less than control (RFP+) derived stroma but to no statistical significance (Figure
27A and B). Very few β-gal+ cells co-expressed FAP, FSP, α-SMA or CD31.
However, the overall prevalence of GFP+ cells co-expressing FAP, FSP, α-SMA or
CD31 in tumors (9.6%+/-4.9%) of CD44KO BMT mice was greater than β-gal+ cells
expressing FAP, FSP, α-SMA or CD31 in the same tumors (0.6%+/-0.4%; Figure
27B). Furthermore, co-expression of both GFP+/FAP+ and GFP+/FSP+ cells was
greater than β-gal+/FAP+ and β-gal+/FSP+ cells, respectively. But this trend did not
reach statistical significance less than 0.05 (FAP+ comparison: p<0.1; FSP+
comparison: p<0.06).
Interestingly, there were more GFP+ co-stained TAF cells in the tumors from the
CD44KO BMT mice as compared to the Red BMT (control) mice. The difference
was significant (p<0.01) when comparing co-stained GFP+/FSP+ cells between the
two BMT groups. (Figure 27C) This suggests the host (GFP+) fibroblastic
incorporation into the tumor microenvironment was enhanced in the CD44KO BMT
mice compared to the Red BMT mice. There is less β-gal+ expressed FAP
(0.025%+/-0.02%) or FSP (0.026%+/-0.01%) compared to RFP+ expressed FAP
(0.26%+/-0.08%) or FSP (0.21%+/-0.06%); however, the difference was trending
towards but never reached statistical significance less than 0.05 (Figure 27D).
Finally, without analyzing the origin of the cell, whether bone marrow or host
derived, the total percentages of tumor supportive stromal markers (α-SMA, CD31,
FAP and FSP) per tumor are lower overall in the CD44KO BMT mice as compared
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to the WT Red BMT mice but none of the percentages reach statistical significance
(Figure 27E).
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Figure 25. Example analysis of marker co-expression by InForm Software.
Image was taken using 20x oil lense with CRi attachment and Nuance Software.
Initial image was spectrally unmixed to show each image component by
wavelength. In this case, fluorescent stains include DAPI, Alexa488 and Alexa594.
(A) DAPI alone; (B) 594+DAPI; (C) 488+DAPI; (D) 488+594; (E) Complete image
(F) zoomed in section shows 594+ and 488+ stain on a single cell. (G) Fluorescent
intensity overlay is yellow wherever 594+ and 488+ are overlapped and is further
depicted by white arrow. (H) Cell segmentation based on nuclear DAPI staining
designates every cell with a circle highlighted by a surrounding membrane. (I)
Individual fluorescent intensity for each cell in imaged are plotted. White box
surrounds data points depicting co-localized intensities that were highlighted by
white arrowheads.
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Figure 26. Fluorescent images of EO771 tumors in mice with CD44KO BMT or
Red BMT. All images were spectrally unmixed and then subjected to a co-staining
algorithm using InForm Software. The yellow color in the images is the enhanced
image of the co-stained overlay. For each marker analyzed, there is a co-stain with
the host (GFP) and the BMT (β-Gal for CD44KO and RFP for tdTomato). The
markers used to assess double positive staining include: (A) FAP, (B) FSP, (C) αSMA and (D) CD31.
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Figure 27. Statistical summary of tumor stroma origin. Percentage of total
single stained or double positive (DP) cells per tumor was calculated across 5
tumors and 10 images per tumor. DP is defined as one cell origin marker (GFP+,
RFP+ or β-gal+) plus one stroma marker (α-SMA, FSP, FAP or CD31) (A)
Percentage of DP stained cells within the tumors engrafted in Red BMT recipient
mice. There was a trend toward more GFP co-stained cells, however there was only
a statistical significance between the CD31 co-stained GFP versus RFP(p<0.001)
(B) Percentage of DP stained cells within the tumors engrafted in the CD44KO BMT
recipient mice. There was a trend toward higher number of GFP+ co-stained cells.
GFP+/FAP+ versus β-gal+/FAP+ was not statistically significant (p<0.1) and
GFP+/FSP+ versus β-gal+/FSP+ was not statistically significant (p<0.06). (C) The
presence of GFP+/FSP+ co-stained cells was higher in the CD44KO BMT tumors
than in the Red BMT tumors (p<0.01) (D) Neither the difference between βgal+/FSP+ and RFP+/FSP+ cells nor the difference between β-gal+/FAP+ and
RFP+/FAP+ cells reached statistical significance. (E) Average percentage of marker
expression per image regardless of co-stain shows a trend toward more positive
staining for every marker in the Red BMT tumors compared to the CD44KO BMT
tumors, however, none reached statistical significance (p> 0.1).
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4.0 Discussion
4.1 Role of CD44 in MSC tumor tropism
It is well established that MSC have an inherent tropism for sites of inflammation
(112, 141, 144), including the tumor microenvironment (91, 110, 120, 145).
However, the mechanism of migration has not yet been fully elucidated. In these
studies, tumor tropic MSC migration was impeded both in vitro and in vivo through
the inhibition of the cell surface receptor CD44. Several techniques were utilized in
order to inhibit MSC migration including stable knockdown of CD44 and two CD44
antagonists: a soluble CD44 receptor (146) and a hyaluronan oligomer (147).
Similar to leukocyte migration, there are numerous factors that have the potential to
induce chemotropic MSC migration. Several chemokines and growth factors have
been identified to play a role in the migration of MSC towards tumors including
CCL2,

PDGFb,

SDF-1,

(68,

70,

115).

Once

recruited

to

the

tumor

microenvironment, the MSC themselves secrete a variety of chemokines to
perpetuate the chemoattractive gradient.

MSC initially were evaluated for the

receptor expression level of respective chemotropic factors secreted by tumor cells.
CD44 was ultimately chosen for further study for two reasons; first, because of the
discrepancy in receptor expression levels between flow cytometry and western blot
data and second, because of the elevated levels of OPN expressed from the highly
chemoattractive Skov-3 tumor cells. A categorical data analysis of over 200 clinical
papers has shown OPN over-expression to be associated with tumor progression
and poor survival among patients in several cancers including lung, breast, prostate
and head and neck (148). Furthermore, in triple negative breast cancers that have a
large population of mesenchymal-like cells within the tumor, OPN levels are
significantly higher than non-triple negative (149). Lastly, OPN has been shown to
be chemotactic factor important in the migration of MSC to bone fractures (104).
In the first set of experiments, we sought to inhibit MSC migration in vitro through a
series of methods using a transwell migration assay. MSC migration toward SCM
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was inhibited between 55-80% compared to control MSC using both transient and
stable knockdown of CD44 in MSC, or using neutralizing antibody, s44 or oHA.
These data are in accord with previously published data that showed the
significance of CD44 in wound-induced fibroblast migration (150).
Next, we used the soluble CD44 receptor to inhibit the migration of MSC to bilateral
engrafted Skov-3 tumors in SCID mice. Analyzed by bioluminescent imaging, ffLuclabeled MSC migrated towards rLuc-labeled Skov-3 but in the presence of the
soluble CD44 migration was inhibited by 50%.
To further elucidate a mechanism of migratory inhibition, CD44-labeled MSC were
analyzed by confocal microscopy in the presence and absence of SCM with and
without oHA. Nuclear localization of CD44 increased in MSC under SCM however
not in the presence of oHA. In order for nuclear translocation to occur, CD44 must
undergo a proteolytic extracellular cleavage followed by a γ-secretase cleavage of
the intracellular domain (151-154). We used an MMP 14 inhibitor in combination
with SCM to show the inhibition of CD44 cleavage products in MSC. Under those
same conditions, MSC migrated 75% less than control MSC.
Nuclear translocation of CD44 has been shown to form a complex with Stat3 and
p300 under to modulate Cyclin D and CD44 transcription (98, 152). Therefore, we
screened the gene expression of factors involved in cellular migration to ask
whether CD44 could influence migration through transcriptional regulation. The
transcription factor, Twist was found to be up regulated in MSC under SCM by RTPCR and Western blot. This protein is typically expressed in mesenchymal-like cells
and has been associated with migration, invasion and angiogenesis (125, 126, 155157). Using our shCD44 MSC, we are able to show a decrease in Twist gene
expression similar to the inhibition achieved with s44 or MMP inhibitors compared to
naïve MSC under SCM. This decrease in Twist expression is also visible at the
protein level between shNeg MSC and shCD44 MSC under SCM. Furthermore,
tumor tropic migration can be partially restored in shCD44 MSC with the ectopic
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expression of Twist. Finally, we show the association between CD44 and the Twist
proximal promoter by ChIP at 24 hours, and a stronger association at 30 minutes
following SCM.
MSC migration toward the tumor microenvironment is a double edged sword.
Inducing a better migratory response could be beneficial to the therapeutic potential
of the MSC as targeted gene therapy delivery vehicle (77, 135, 145, 158, 159). And
alternatively, inhibition of naïve MSC migration toward the tumor microenvironment
could be beneficial in the reduction of tumor progression by impeding supportive
stromal cell accumulation (25, 160). In this regard, the manipulation of CD44 on the
surface of MSC may be used to either enhance or inhibit the migration to the tumor
microenvironment.
4.2 MSC contribution to the tumor microenvironment through TAF
Tumors acquire their stroma through four different proposed mechanisms: the
recruitment of (1) local tissue-derived stem cells, (2) local tissue derived fibroblasts,
(3) bone marrow derived stromal cells and (4) epithelial to mesenchymal
transitioned tumor cells (7, 92, 161, 162).

In these experiments, we show the

potential for MSC participation as tumor stroma (TAF) through differentiation under
long term SCM both in vitro and in vivo. Moreover, we show the potential for the
TAF to promote tumor growth and proliferation within the tumor as compared to
tumors without exogenously added MSC.
TAF are a heterogeneous population of cells that have several functions within the
tumor microenvironment (28):
1) to maintain a supply of growth factors;
2) to support angiogenesis;
3) to aid in structural remodeling.
To elucidate whether the MSC could contribute to each of these three functions, we
analyzed long term (21-31 day) tumor conditioned MSC. In vitro we saw an increase
in growth factor secretion of IL-6, TGF-β and VEGF in response to SCM. The LT119

MSC showed an increase in pericyte markers including α-SMA and the
myofibroblast marker desmin. Immunohistochemical staining for desmin and α-SMA
have been correlated with disease-free survival and each individually show a
reduced recurrence-free survival compared to tumors with little or no positive
staining (163). Increased expression of Tn-c and TSP1 in LT-MSC are remodeling
proteins indicative of vascular sprouting modulation (164). Lastly, two proteins
involved in active wound repair are FAP and FSP, both of which are increased in
the LT-MSC. FAP and FSP are up regulated in activated fibroblasts in granulation
tissue of healing wounds and likewise in tumor stroma. The function FSP has been
linked to modulation of invasion through facilitating extra-cellular matrix adhesion
and degradation (36, 165). FAP expression in the reactive tumor stroma has been
shown to be a positive prognostic marker in invasive ductal carcinoma of the breast
(166); however others have proposed to target FAP in order to target tumor stroma
specifically (167).
In vivo, we admixed MSC and Skov-3 tumor cells in order to support our in vitro
findings that MSC are capable of TAF differentiation. Three months following tumor
engraftment, we sacrificed the SCID mice and paraffin embedded the tumors for
immunohistochemical analysis. Individual staining for each of the aforementioned
markers showed a marked difference between admixed tumors and tumors alone.
Furthermore, these experiments were conducted in xenograft models of both breast
(MDA-231) and pancreatic (Panc-1) tumors to show the potential of the MSC to
support tumor growth as TAF in other adenocarcinoma models (25). The markers
were not co-stained because of the potential of the MSC to differentiate into a
variety of TAF. Unpublished data from our lab suggests that the FAP and FSP
markers are likely to co-express and the pericyte or myofibroblast markers like αSMA and desmin are likely to co-express. Just as the MSC is a heterogeneous
population of cells, the population of TAF it gives rise to is also a heterogeneous
population (168).
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Finally, we looked at the tumor growth potential between our admixed MSC/Skov-3
tumors versus the Skov-3 tumors alone and saw a growth advantage at the later
stage (day 65-70) of tumor growth following an initial tumor growth retardation in the
admixed tumors. Also, to confirm that the stromal enhancement of tumor growth
was specifically from the human MSC and not from murine stromal cells within or
xenograft model, we conducted an in vitro tumor growth assay to measure the
proliferation of the tumor cells in the presence of human and murine MSC and
fibroblasts. Our results confirmed that the human MSC offered a significant growth
advantage that could not be afforded by the murine cells. The proliferation potential
offered by the human MSC to the Skov-3 ovarian tumor cells was confirmed to be
MSC secreted IL-6.

Our lab had previously shown the significance of MSC

secreted EGF on the proliferation of estrogen receptor positive breast cancer cells
(169, 170) using this same method.
It is important to note the differences between the stromal support offered by the
MSC as they differentiate into TAF under various TCM, be it ovarian or breast
tumors media. We showed the similarity between stromal markers expressed in
xenograft ovarian, breast and pancreatic tumor models. However, we did not
attempt to define potential differences in expression pattern or expression level that
may result from variations between tumor models. The heterogeneity of the TAF is
important to the global participation potential in many wounded environments from
ovarian carcinomas to gastrointestinal stromal tumors to sarcomas. TAF have a
biological impact on tumor progression through their ability to be matrix-modulating
through synthesis or degradation (activated fibroblast), contractile (myofibroblast),
angiogenic supportive (pericyte) and sustenance (growth factors) providing cells
(171).
4.3 Regulating CD44 expression on MSC impedes differentiation into TAF
After establishing the importance of CD44 to the tumor tropic migratory capacity of
MSC, we sought to investigate the role of CD44 in the trans-differentiation potential
of MSC into TAF. We used our stable CD44 knockdown cell line of human MSC to
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analyze their capacity to support angiogenesis in vitro. shCD44MSC were unable to
support tube formation compared to naïve or shNeg MSC control cells. MSC
express pro-angiogenic growth factors that can induce HUVEC tube formation in
vitro including VEGF A, VEGF C (172), EGF (173), IL-8 (174) and OPN (175).
When we compared the growth factor gene expression in tumor conditioned
shCD44MSC versus shNeg MSC controls, we observed a decrease in expression
of VEGF C, EGF and IL-8. Interestingly, this gene expression change could be
rectified by over expression of Twist in the shCD44MSC. Twist expression within
endothelial cells is known to be important for the tube formation (157), herein we
provide evidence that ectopic Twist expression can enhance the growth factor
secretion profiles of shCD44MSC but we have not yet provided evidence that
ectopic expression of Twist in shCD44MSC can fully rescue the tube formation
capability of the MSC.
After observing growth factor expression differences between shCD44MSC and
control shNeg MSC, we looked at the long term differentiation potential of the
shCD44MSC under SCM. The shCD44MSC were deficient in the expression of αSMA, PDGFR-β, FAP, FSP and TSP1 compared the shNeg MSC. Interestingly, the
expression of vimentin was similar between the two when looking at the full length
product; however there was a clear difference in the cleavage products. Cleavage
of vimentin and other intermediate filament proteins like desmin are important in the
cytoskeletal remodeling of cells during injury because they aid in cell fusion and
cytoskeletal rearrangement and may elucidate an important deficiency of the
shCD44MSC compared to the WT counterpart (176, 177).
To further elucidate the role of CD44 expression on MSC we utilized a transgenic
CD44 knockout mouse. The murine CD44KO MSC also showed a decreased
migratory propensity in vitro, and showed a decrease in Twist, FAP and a slight
decrease in α-SMA and FSP expression. One interesting similarity between the
murine CD44KO MSC and the human shCD44MSC was the expression of PDGFRβ which was reduced, but also appeared in a single band as opposed to the double
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band pattern seen in naïve MSC. CD44 and PDGFRβ have been shown to form a
complex in which hyaluronan activated CD44 inhibited PDGFRβ tyrosine kinase
activity in dermal fibroblasts (178). This interaction suggests an important cross talk
that takes place between CD44 and other cell surface receptors on the MSC that is
not yet elucidated.
The last set of experiments conducted were a series of in vivo tumor models to
study the role of CD44 deficient MSC or stromal cells in the tumor
microenvironment. First, EO771 murine breast tumors developed SC in either
CD44KO mice or in their WT counterpart (a transgenic tdTomato labeled mouse).
Daily caliper measurements revealed a growth advantage in the WT mice compared
to the CD44KO mice. Furthermore, the CD44KO mice had a significant survival
advantage compared to the WT mice on day 30, when all mice were sacrificed due
to tumor burden. Upon immunohistochemical analysis, tumors from WT mice had
more dense tumors by H&E staining compared to tumors in the CD44KO mice. Of
note, EO771 tumors are rapidly growing tumor with large regions of tumoral
hemorrhaging that make overall analysis between stromal regions of the tumor
difficult to analyze because of the large amount of Eosin stained red blood cells that
mask the stained stromal cells. In the stroma-rich gastrointestinal stromal tumors,
the CD44 cleavage activity positively correlated both with mitotic index and
negatively correlated with disease free survival (179). These correlations support
both the growth advantage and the survival advantage of the CD44KO mice in our
breast cancer model.
The next in vivo experiment was conducted in SCID mice using a 4T1 murine breast
cancer model with and without 1:1 ratio of admixed CD44KO MSC or WT MSC.
Analysis of tumor sections revealed that CD44KO MSC admixed tumors had lower
expression of α-SMA, FAP, FSP and CD31 staining compared to WT MSC admixed
tumors. These data were consistent with the decrease in TAF marker expression on
in vitro tumor conditioned CD44KOMSC.
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When tumor size was evaluated in CD44KO MSC admixed 4T1 tumors versus WT
MSC admixed 4T1 tumors versus 4T1 tumors, tumors were engrafted contralateral
in the inguinal fat of the mice. The admixed tumors were placed opposite to the 4T1
tumors alone. In group 1, the CD44KO MSC admixed tumors were significantly
smaller than its contralateral 4T1 tumor. There was not a significant difference
between WT MSC admixed tumors and the respective contralateral 4T1 tumors.
These data are reminiscent of the possibility of systemic instigation facilitating or
competing with the growth of the opposing tumor. This idea has been previously
reported in the growth potential of secondary and/or metastatic lesions occurring
from OPN over-expression (180). We looked at human levels of OPN in
shCD44MSC and there was a decrease in expression level between shNeg MSC,
however, under SCM, the difference was ablated. Future studies will address the
murine expressed growth factors systemically or individually in the MSC and the
4T1. Lastly, there was a significant discrepancy in F4/80+ macrophage infiltration
between the CD44KO MSC admixed tumors and the WT admixed tumors and the
4T1 tumors alone. This discrepancy may explain the tumor size differences if the
tumor infiltrating macrophages are tumor supportive and secrete pro-growth and
pro-angiogenic factors including VEGF, bFGF, TNFα, MMPs, IL-6 and IL-8 (181183).
Our final in vivo experiment utilized an allogeneic bone marrow transplantation to
investigate the CD44KO bone marrow contribution to the tumor microenvironment.
Consistent with our previous experiments, the tumor stroma derived from the
CD44KO bone marrow was less than from the WT Red bone marrow, however no
statistical significance was reached. Unlike the aforementioned studies, the tumor
stroma contribution from the GFP+ local host tissues could be distinguished from
the transplanted β-gal+ CD44KO bone marrow or the RFP+ Red bone marrow.
The incorporation of FAP+, FSP+, α-SMA+ and CD31+ components within the
tumor microenvironment were analyzed by two separate methods. The first method
provided a quantitative analysis of host (GFP+) stromal cells versus bone marrow
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derived stromal cells (RFP+ or β-gal+) that co-stained with FAP+, FSP+, α-SMA or
CD31 within the tumor. These data suggest that the bone marrow contribution to the
tumor microenvironment is less than 1%. Additionally, we observed CD44KO bone
marrow derived cells provide less FAP+ and FSP+ stromal components compared
to WT Red (RFP+) bone marrow derived cells. Reports in the literature suggest that
bone marrow derived cells found within the tumor microenvironment greatly vary
and are dependent on tumor stage (184-186).
Using co-staining as our method of analysis, we observed a greater infiltration of
TAF-stromal cells originating from the GFP+ host as opposed to RFP+ or CD44KO+
bone marrow in both the WT control Red BMT mice and the CD44KO BMT mice. In
this model, there was a greater presence of host (GFP+) derived FSP+ cells within
the tumors in CD44KO BMT mice compared to WT Red BMT mice. This finding was
contradictory to our previous experiment showing that overall FSP expression was
decreased in CD44KO admixed tumors. This contradiction may be due to the nonphysiological ratio of admixed tumor:MSC ratio that has often been a source of
discrepancy within the field (8, 187). Furthermore, the EO771 murine breast model
utilized for the syngenic BMT experiments in immunocompetent mice differs from
the previous 4T1 tumor admixing model in the immunocompromised mouse
experiments and may be a source of discrepancy between the two results.
The second method of analysis measured only the overall incorporation of FAP+,
FSP+, α-SMA+ or CD31+ within the tumor regardless of the origin. Under these
parameters, the tumors grown in the CD44KO BMT had less overall incorporation of
all four markers as compared to tumors in the WT Red BMT control mice. These
findings were in agreement with our previous results in the xenograft 4T1 tumor
model.
In our model, we propose that the recruitment of CD44KO bone marrow derived
stroma to the tumor microenvironment is diminished compared to recruitment of WT
bone marrow derived stroma. We quantify the tumor stroma components by FAP+
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and FSP+ markers associated with pathological disease and by α-SMA+ and
CD31+ markers associated with neo-angiogenesis.

We provide evidence that

CD44 expression is significant to the bone marrow derived stromal cell population
that contributes to the tumor microenvironment. Several studies have established
CD44 as a modulator of invasiveness, chemoprotection and stemness in the
context of cancer cells (99, 124, 188). Other investigators have shown the
significance of CD44 expression in leukocyte populations. Khan and colleagues
showed that CD44 expression is important for leukocyte emigration, but not for
subsequent migration within the tissues during chronic inflammation (189). And,
Rajasagi and colleagues have shown the importance of CD44 in the repopulation of
the T cell population within the thymus following myeloablation/bone marrow
reconstitution (190). Ultimately, our tumor stroma markers account for a fraction of
the potential differences within the CD44KO bone marrow stromal cells. There are
several other markers including chemokines (191), growth factors such as TGF-β
(150) and proteases that are potentially altered by the deficiency in CD44 signaling
in the integration of tumor stroma.
When tumors recruit the stromal elements of the microenvironment such as the
vascular and (myo) fibroblastic components, the majority of the cells are of local
origin derived from host tissue as opposed to bone marrow derived cells. However,
when the demand for stroma exceeds the local environment’s capacity to deliver,
the stroma will be systemically recruited from the bone marrow. If the bone marrow
stroma is CD44 deficient, the incorporation of the bone marrow contributed tumor
stroma will be negligible. However, the local WT derived stromal cells can
supersede the CD44 deficient stroma in order to maintain a stroma-rich tumor
microenvironment.
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